agen-ex1026_375.htm

[******] - Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

This OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 20, 2018 (the “Execution Date”) by and between Agenus Inc., a Delaware corporation (“Agenus”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). Agenus and Gilead are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”

WHEREAS, Gilead wishes to obtain, and Agenus wishes to grant, an option to license the Agenus IP with respect to Licensed Products in the Field in the Territory (each, as defined below) on the terms and conditions set forth in this Agreement;

WHEREAS, simultaneously with entering into this Agreement, the Parties are entering into the License Agreement and the Option and License Agreement (AGEN2373) (each, as defined below); and

WHEREAS, simultaneously with entering into this Agreement, the Parties are entering into a stock purchase agreement and certain related agreements, pursuant to which Agenus will issue and Gilead will purchase shares of capital stock of Agenus on the terms and conditions set forth therein (the “Stock Purchase Agreement”).

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

Unless specifically set forth to the contrary herein, the following terms shall have the respective meanings set forth below.

1.1“Accounting Standards” means U.S. generally accepted accounting principles in effect at the relevant time, consistently applied.

1.5“Additional Development Costs” has the meaning set forth in Section 9.3.4(a).

1.6“Affiliate” means any Person which, directly or indirectly through one (1) or more intermediaries, controls, is controlled by, or is under common control with a Party. For purposes of this Section 1.6 only, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect to a Person means: (a) direct or indirect ownership of fifty percent (50%) or more of the voting securities or other voting interest of any Person (including attribution from related parties); or (b) the possession, directly or indirectly, of the power to direct, or cause

the direction of, the management and policies of such Person, whether through ownership of voting securities, by contract, as a general partner, as a manager, or otherwise.

1.9“Agenus Development Plan” means the initial, high-level plan for the Development of the Licensed Antibodies and the Licensed Products set forth on Exhibit A, as such plan may be amended from time to time in accordance with this Agreement.

1.13“Agenus Know-How” means any Know-How Controlled by Agenus or any of its Affiliates as of the Execution Date or thereafter during the Term which is [******] for the Development, Manufacture, or Commercialization of the Licensed Products in the Field in the Territory.

1.15“Agenus Patents” means, collectively, [******]. Without limiting the foregoing, Schedule 1.15 sets forth a complete and accurate list of all Agenus Patents as of the Execution Date, which list identifies [******]. Schedule 1.15 shall be updated as necessary from time to time to reflect the then-current Agenus Patents, [******].

1.19“ANDA” means an abbreviated new drug application filed pursuant to the requirements of the FDA pursuant to 21 C.F.R. Part 314 to obtain regulatory approval for a product in the United States, or the equivalent application or filing in another country (as applicable).

1.20“Annual Net Sales” means, on a Licensed Product-by-Licensed Product basis, total Net Sales by Gilead, its Affiliates, and its Sublicensees in the Territory of such Licensed Product in a particular Calendar Year, calculated in accordance with Accounting Standards.

1.21“Antibody” means one or more molecules which comprise or consist of one or more immunoglobulin domains, or fragment(s) thereof, that [******].

1.23“Antitrust Law” means any federal, state, or foreign statutes, rules, regulations, orders, or decrees that are designed to prohibit, restrict, or regulate actions having the purpose or effect of monopolization, lessening of competition, or restraint of trade, including the HSR Act.

1.24“Applicable Law” means all applicable laws, statutes, rules, regulations, treaties (including tax treaties), orders, judgments or ordinances having the effect of law of any national, multinational, federal, state, provincial, county, city, or other political subdivision, including, to the extent applicable, GCP, GLP, and GMP, as well as all applicable data protection and privacy laws, rules, and regulations, including, to the extent applicable, the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act and the Health Information Technology for Economic and Clinical Health Act and the EU Data Protection Directive (Council Directive 95/46/EC) and applicable laws implementing the EU Data Protection Directive and the General Data Protection Regulation (2016/679 ), the Foreign Corrupt Practices Act of 1977, or any comparable laws in any country, and all export control laws.

1.29“Bispecific Antibody” means a molecule, or a covalently linked plurality of molecules, which comprise(s) two (2) different [******], one of which [******] and the other of which [******].

1.30“BLA” means a Biologics License Application filed with the FDA in the United States with respect to a Licensed Product, as defined in Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et seq., or any non-U.S. counterpart of the foregoing.

1.31“Business Day” means any day other than: (a) a Saturday or Sunday or any day on which commercial banks in Boston, Massachusetts, and San Francisco, California, are authorized or required by Applicable Law to remain closed; or (b) December 26 through December 31.

1.32“Calendar Quarter” means each of the three (3) month periods ending March 31, June 30, September 30, and December 31; provided, that: (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete such three (3)-month period thereafter; and (b) the final Calendar Quarter of the Term shall end on the last day of the Term.

1.33“Calendar Year” means the period beginning on the Effective Date and ending on December 31 of the calendar year in which the Effective Date falls, and thereafter each successive period of twelve (12) consecutive calendar months beginning on January 1 and ending on December 31; provided , that the final Calendar Year of the Term shall end on the last day of the Term.

1.35“Clinical Trial” means any human clinical trial of a pharmaceutical or biological product.

1.38“COGS” means, with respect to the supply of a Profit-Share Product, the product of the Standard Cost of Manufacturing of such Profit-Share Product and the number of units of such Profit-Share Product.

1.39“Combination Product” means: (a) a product that contains a Licensed Product and one (1) or more [******] (each, an “Additional Active”); or (b) a Licensed Product that is co-packaged or combined with one (1) or more Additional Actives, and such Licensed Product and Additional Actives are sold for a single price.

1.40“Commercialization” means any and all activities directed to the commercialization of a product, including marketing, detailing, promotion, market research, distributing, order processing, handling returns and recalls, booking sales, customer service, administering, and commercially selling such product, importing, exporting, and transporting such product for commercial sale, and seeking Pricing Approval of a product (if applicable), whether before or after Regulatory Approval has been obtained, as well all regulatory compliance with respect to the foregoing. For clarity, Commercialization does not include: (a) Manufacturing; or (b) any Clinical Trials and other trials commenced after Regulatory Approval. When used as a verb, “Commercialize” means to engage in Commercialization.

1.41“Commercialization Budget” means the high-level budget for conducting Commercialization of the Licensed Products in the U.S. in accordance with the Commercialization Plan [******], in each case, during the Profit-Share Term, as such budget may be amended from time to time in accordance with this Agreement.

1.42“Commercialization Plan” means the high-level plan for the Commercialization of the Licensed Products in the U.S. [******], in each case, during the Profit-Share Term, as such plan may be amended from time to time in accordance with this Agreement.

1.45“Compulsory License” means, with respect to a Licensed Product in a country or territory, a license, or rights granted to a Third Party by a governmental agency within such country or territory to sell or offer for sale such Licensed Product in such country or territory under any Patents or Know-How owned or controlled by either Party or its Affiliates, without direct or indirect authorization from such Party or its Affiliates.

1.47“Confidential Information” means, with respect to a Party, all confidential and proprietary information, including chemical or biological materials, chemical structures, sequence information, commercialization plans, correspondence, customer lists, data, development plans, formulae, improvements, Inventions, Know-How, processes, regulatory filings, reports, strategies, techniques, or other information, in each case, that are disclosed by or on behalf of such Party to the other Party pursuant to this Agreement, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other Party by or on behalf of the disclosing Party in oral, written, visual, graphic, or electronic form.

1.48“Control,” “Controls,” or “Controlled” means with respect to any Patent, Know-How, other intellectual property right, or Confidential Information, the ability of a Party or its Affiliates, as applicable (whether through ownership or license (other than a license granted in this Agreement)) to grant to the other Party the licenses or sublicenses as provided herein, or to otherwise disclose such intellectual property right or Confidential Information to the other Party, without violating the terms of any then-existing agreement with any Third Party at the time such Party or its Affiliates, as applicable, would be required hereunder to grant the other Party such license or sublicenses as provided herein or to otherwise

disclose such intellectual property right or Confidential Information to the other Party. Notwithstanding the foregoing, a Party will be deemed not to Control any Patent, Know-How, other intellectual property right, Confidential Information, compound, or molecule (including any antibody) that is [******] except: [******].

1.49“Cover” means, with reference to [******], that the making, using, offering to sell, selling, importing, or exporting of such product would [******].

1.51“Damages” means all losses, costs, claims, damages, judgments, liabilities, and expenses (including reasonable attorneys’ fees and other reasonable out-of-pocket costs in connection therewith).

1.53“Data Package Request Notice” has the meaning set forth in Section 2.3.2(a).

1.54“Default” means: (a) any material breach, violation, or default; (b) the existence of circumstances or the occurrence of an event that with the passage of time or the giving of notice or both would constitute a material breach, violation, or default; or (c) the existence of circumstances or the occurrence of an event that, with or without the passage of time or the giving of notice or both, would give rise to a right of termination, renegotiation, acceleration, or material change of terms.

1.56“Detail” means an interactive face-to-face visit by an authorized salesperson or agent (each, a “Sales Representative”) with a healthcare provider having prescribing authority and who is within the target audience, during which approved uses, safety, effectiveness, contraindications, side effects, warnings, or other relevant characteristics of a pharmaceutical or biological product are discussed in an effort to increase prescribing preferences of a pharmaceutical or biological product for its approved uses. Details shall not include: (a) activities conducted by medical support staff; or (b) e-details, activities conducted at conventions or similar gatherings, or activities performed by market development specialists, managed care account directors, and other personnel not performing face-to-face sales calls or not specifically trained with respect to a pharmaceutical or biological product. “Detailing” means the act of performing Details.

1.57“Development” means: (a) research activities (including drug discovery, identification, or synthesis) with respect to a product; or (b) preclinical and clinical drug development activities and other development activities with respect to a product, including test method development and stability testing, toxicology, formulation, process development, qualification and validation, quality assurance, quality control, Clinical Trials (including Clinical Trials and other trials commenced after Regulatory Approval), statistical analysis and report writing, the preparation and submission of INDs and MAAs, regulatory affairs with respect to the foregoing, and all other activities necessary or useful or otherwise requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining a Regulatory Approval. For clarity, “Development” does not include Manufacturing. When used as a verb, “Develop” means to engage in Development.

1.58“Development and Manufacturing Agreement” means any contract or agreement, other than any Upstream License Agreement, between Agenus (or any of its Affiliates, as applicable) and any Third Party which is related to the Development or Manufacture of any Licensed Antibody or Licensed Product.

1.59“Development Costs” means, with respect to the Profit-Share Product: (a) those FTE Costs and Third Party Expenses, in each case, [******]; and (b) Other Expenses [******].

1.63“Early Exercise Comment Notice” has the meaning set forth in Section 2.3.2(b).

1.67“EU” means all countries that are officially recognized as member states of the European Union at any particular time.

1.68“EU Regulatory Approval” means Regulatory Approval [******] of a Licensed Product by EMA or the relevant Regulatory Authority in [******] of the Major European Markets.

1.70“Executive Officers” means: (a) with respect to Agenus, [******] or his/her designee or successor with equivalent responsibilities; and (b) with respect to Gilead, [******] or his/her designee or successor with equivalent responsibilities.

1.71“Existing Development and Manufacturing Agreement” means any Development and Manufacturing Agreement in effect as of the Execution Date.

1.72“Existing Regulatory Materials” has the meaning set forth in Section 5.2.1.

1.73“Existing Upstream License Agreements” has the meaning set forth in Section 1.226.

1.75“Field” means any and all uses or purposes, including the treatment, prophylaxis, palliation, diagnosis, or prevention of any human or animal disease, disorder, or condition.

1.76“First Commercial Sale” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the first sale of such Licensed Product in such country for use or consumption by the general public (following receipt of all Regulatory Approvals that are required in order to sell such Licensed Product in such country) and for which any of Gilead or its Affiliates or Sublicensees has invoiced sales of Licensed Products in the Territory; provided, however, that the following shall not constitute a First Commercial Sale: [******].

1.78“FTE” means the equivalent of a full-time employee’s performance of [******] hours of work time over a Calendar Year [******].

1.79“FTE Costs” means an amount equal to the product of the FTE Rate and actual FTEs who performed work under the Gilead Development Plan or the Commercialization Plan (calculated in accordance with Section 1.78). For clarity, the cost of activities of contract personnel shall be charged as Third Party Expenses.

1.80“FTE Rate” means a mutually agreed-upon cost (or applicable cost within a schedule of costs) per FTE, which shall be [******].

1.82“GCP” means the applicable then-current ethical and scientific quality standards for designing, conducting, recording, and reporting Clinical Trials as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, in the United States, Good Clinical Practices established through FDA guidances, and, outside the United States, Guidelines for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6).

1.84“Gilead Development Budget” means the high-level budget for conducting U.S. Development of the Licensed Products pursuant to the Gilead Development Plan [******], in each case, to the extent during the Profit-Share Term, as such budget may be amended from time to time in accordance with this Agreement.

1.85“Gilead Development Plan” means (a) the plan for the Development of the Licensed Products [******], in each case, during the Profit-Share Term, as such plan may be amended from time to time in accordance with this Agreement, which plan shall describe [******], as such plan may be amended from time to time in accordance with this Agreement.

1.88“GLP” means the applicable then-current good laboratory practice standards as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, in the United States, those promulgated or endorsed by the FDA in U.S. 21 C.F.R. Part 58, or the equivalent thereof as promulgated or endorsed by the applicable Regulatory Authorities outside of the United States.

1.89“GMP” means all applicable then-current good manufacturing practice standards relating for fine chemicals, intermediates, bulk products, or finished pharmaceutical or biological products, as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, as applicable: (a) all applicable requirements detailed in the FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211; (b) all applicable requirements detailed in the EMA’s “The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products;” and (c) all Applicable Law promulgated by any Governmental Authority having jurisdiction over the manufacture of the applicable compound or pharmaceutical or biological product, as applicable.

1.90“Governmental Authority” means any: (a) federal, state, local, municipal, foreign, or other government; (b) governmental or quasi-governmental authority of any nature (including any agency, board, body, branch, bureau, commission, council, department, entity, governmental division, instrumentality, office, officer, official, organization, representative, subdivision, unit, and any court or other tribunal); (c) multinational governmental organization or body; or (d) entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military, or taxing authority or power of any nature.

1.92“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C. § 18a).

1.96“IND” means an investigational new drug application (including any amendment or supplement thereto) submitted to the FDA pursuant to U.S. 21 C.F.R. Part 312, including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) outside the U.S. for the investigation of any product in any other country or group of countries (such as a Clinical Trial Application in the EU).

1.97“IND Acceptance” means, with respect to an IND, the earlier of: (a) receipt by a Party, its Affiliate or a Sublicensee of written confirmation from a Regulatory Authority or other applicable Person that Clinical Trials may proceed under such IND; or (b) expiration of the applicable waiting period after which Clinical Trials may proceed under such IND.

1.98“Indemnification Claim Notice” has the meaning set forth in Section 14.4.1.

1.104“Information Request Notice” has the meaning set forth in Section 2.3.1.

1.106“Initial Licensed Antibody” has the meaning set forth in Section 1.117(i).

1.107“Initial Licensed Product” means the Licensed Product that constitutes, incorporates, comprises, or contains the Initial Licensed Antibody [******].

1.109“Invention” means any process, method, composition of matter, article of manufacture, discovery, or finding that is conceived or reduced to practice.

1.113“Know-How” means algorithms, data, information, Inventions, knowledge, methods (including methods of use or administration or dosing), practices, results, software, techniques, technology, and trade secrets, including analytical and quality control data, analytical methods (including applicable reference standards), assays, batch records, chemical structures and formulations, compositions of matter, formulae, materials, manufacturing data, pharmacological, toxicological and clinical test data and results, processes, reports, research data, research tools, sequences, standard operating procedures, and techniques, in each case, whether patentable or not, and, in each case, tangible manifestations thereof.

1.115“License Agreement” means the License Agreement, dated the date hereof, by and between the Parties, with respect to the antibody known as AGEN1423.

1.116“License Agreement Effective Date” means the Effective Date as defined under the License Agreement.

1.117“Licensed Antibody” means: (i) the Bispecific Antibody known as AGEN1223 [******] as described in more detail on Schedule 1.117 (the “Initial Licensed Antibody”) and (ii) any other Bispecific Antibody: [******].

1.119“Licensed Product” means [******] product that [******] a Licensed Antibody, [******].

1.123“MAA” means a Marketing Authorization Application, BLA, or similar application, as applicable, and all amendments and supplements thereto, submitted to the FDA, EMA, or any equivalent filing in a country or regulatory jurisdiction other than the U.S. or EU with the applicable Regulatory Authority, to obtain marketing approval for a pharmaceutical or biological product, in a country or in a group of countries.

1.125“Manufacture” means all activities related to the manufacturing of a product or any component or ingredient thereof, including the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of product or any intermediate thereof, including process

development, process qualification and validation, scale-up, commercial manufacture and analytic development, product characterization, stability testing, quality assurance, and quality control.

1.126“Manufacturing CMO” means a Third Party designee of Gilead which performs, or will perform, Manufacturing services with respect to any Licensed Product.

1.134“Operating Expenses” means, with respect to a Profit-Share Product, [******]. Operating Expenses shall be determined [******].

1.136“Option and License Agreements” means, collectively, this Agreement and the Option and License Agreement (AGEN2373).

1.137“Option and License Agreement (AGEN2373)” means the Option and License Agreement, dated the date hereof, by and between the Parties, with respect to the antibody known as AGEN2373.

1.139“Option Early Exercise Review Period” has the meaning set forth in Section 2.3.2(a).

1.144“Option Period” means the period of time commencing on the Effective Date and ending upon the earlier of: (a) [******], as such period may be extended pursuant to Section 2.3; and (b) [******].

1.146“Other Expenses” means, with respect to a Profit-Share Product, the following items, to the extent [******].

1.149“Outstanding Profit-Share Costs” has the meaning set forth in Section 9.3.5(c)(3).

1.153“Patents” means: (a) U.S. patents and patent applications in any country or supranational jurisdiction worldwide; (b) any substitutions, divisionals, continuations, continuations‑in‑part, reissues, renewals, registrations, confirmations, and the like of any such patents or patent applications; (c) foreign counterparts of any of the foregoing; and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions, including any supplementary protection certificates of any of the foregoing.

1.156“Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein.

1.168“Pricing Approval” means any approval, agreement, determination, or decision establishing prices that can be charged to consumers for a pharmaceutical or biological product or that will be reimbursed by Governmental Authorities for a pharmaceutical or biological product, in each case, in a country where Governmental Authorities approve or determine pricing for pharmaceutical or biological products for reimbursement or otherwise.

1.169“Prior CDA” means that certain mutual confidentiality agreement, by and between Agenus Inc. and Gilead dated [******], as amended by (i) that certain letter agreement dated [******] between Agenus Inc. and Gilead, [******]and (ii) that certain letter agreement between Agenus Inc. and Gilead dated [******].

1.170“Profit (Loss)” means, with respect to the Profit-Share Product, Net Sales plus Sublicense Revenues, less COGS less Operating Expenses, in each case, solely to the extent incurred with respect to the U.S.

1.172“Profit-Share Effective Date” means the [******] of the [******] following the [******] in which Agenus delivers the Profit-Share Option Exercise Notice in accordance with Section 9.3.2.

1.173“Profit-Share Opt-Out Effective Date” means the [******] of the [******] following the [******] in which Agenus delivers the Profit-Share Opt-Out Notice in accordance with Section 9.3.5(a).

1.174“Profit-Share Opt-Out Notice” has the meaning set forth in Section 9.3.5(a).

1.175“Profit-Share Opt-Out Option” has the meaning set forth in Section 9.3.5(a).

1.176“Profit-Share Opt-Out Option Exercise Deadline” has the meaning set forth in Section 9.3.5(a).

1.178“Profit-Share Option Exercise Deadline” has the meaning set forth in Section 9.3.1.

1.179“Profit-Share Option Exercise Notice” has the meaning set forth in Section 9.3.2.

1.180“Profit-Share Product” means the Initial Licensed Product for which Agenus has exercised the Profit-Share Option in accordance with Section 9.3.2, but only for so long as the Profit-Share Term for such Initial Licensed Product remains in effect, after which such Initial Licensed Product shall automatically become a Royalty-Bearing Product.

1.181“Profit-Share Term” means the period of time commencing on the Profit-Share Effective Date and expiring upon the earliest of: (a) the Profit-Share Opt-Out Effective Date; (b) the Profit-Share Termination Effective Date; and (c) expiration of the Royalty Term with respect to the Profit-Share Product in the U.S.

1.182“Profit-Share Termination Effective Date” has the meaning set forth in Section 9.3.5(b).

1.183“Prosecution and Maintenance” or “Prosecute and Maintain” means, with regard to a Patent, the preparation, filing, prosecution, and maintenance of such Patent, as well as re-examinations, reissues, appeals, and requests for patent term adjustments with respect to such Patent, together with the initiation or defense of interferences, oppositions, inter partes review, derivations, re-examinations, post-grant proceedings, and other similar proceedings [******] with respect to the particular Patent, and any appeals therefrom. For clarification, “Prosecution and Maintenance” or “Prosecute and Maintain” shall not include any other enforcement actions taken with respect to a Patent.

1.185“Regulatory Approval” means, all approvals, licenses, and authorizations of the applicable Regulatory Authority necessary for the marketing and sale of a pharmaceutical or biological product for a particular Indication in a country or region (including separate Pricing Approvals, as necessary), and including the approvals by the applicable Regulatory Authority of any expansion or modification of the label for such Indication.

1.186“Regulatory Authority” means any national or supranational Governmental Authority, including the U.S. Food and Drug Administration (and any successor entity thereto) (the “FDA”) in the U.S., the European Medicines Agency (and any successor entity thereto) (the “EMA”) in the EU, or any health regulatory authority in any country or region that is a counterpart to the foregoing agencies, in each case, that holds responsibility for development and commercialization of, and the granting of Regulatory Approval for, a pharmaceutical or biological product in such country or region.

1.188“Regulatory Materials” means the regulatory registrations, applications, authorizations, and approvals (including approvals of MAAs, INDs, supplements and amendments, pre- and post-approvals, Pricing Approvals, and labeling approvals), Regulatory Approvals, and other submissions made to or with any Regulatory Authority, including drug master files, for research, development (including the conduct of Clinical Trials), manufacture, or commercialization of a pharmaceutical or biological product in a regulatory jurisdiction, together with all related correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each MAA, IND, and foreign equivalents of any of the foregoing.

1.190“ROW” means all of the countries in the Territory other than the United States.

1.191“Royalty-Bearing Product” means any Licensed Product other than a Profit-Share Product.

1.193“Royalty Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period of time commencing on the First Commercial Sale of any Licensed Product in such country and expiring upon the latest of: [******].

1.194“Royalty Territory” means: (a) the Territory, with respect to Royalty-Bearing Products; and (b) the ROW, with respect to Profit-Share Products.

1.198“Securities Regulators” has the meaning set forth in Section 12.3.1(a).

1.203“Settlement Sublicensee ” means a Third Party that is granted a license or sublicense under a settlement agreement between such Third Party and a Party, any of its Affiliates, or any of its or their respective licensees or sublicensees, which agreement was entered into in connection with an ANDA settlement or similar agreement.

1.204“Standard Cost of Manufacturing” means, with respect to the Profit-Share Product for a given Calendar Year, [******].

1.206“Sublicense Revenues” means all amounts received by Gilead from a Sublicensee in consideration for a sublicense under the licenses granted to Gilead pursuant to this Agreement to Develop and Commercialize Licensed Products in the U.S., excluding: [******].

1.207“Sublicensee” means, with respect to Gilead, a Third Party to whom Gilead has granted a sublicense or license, either directly or indirectly, under the Agenus IP licensed to Gilead by Agenus pursuant to this Agreement, to Develop, Manufacture, or Commercialize the Licensed Products in the Field in the Territory, but excluding: (a) any Third Party acting solely as a distributor; and (b) Agenus and any of its Affiliates.

1.211“Terminated Licensed Product” means: (a) in the case of the termination of this Agreement with respect to a Licensed Product pursuant to Section 15.2 or Section 15.3, the Licensed Product subject to such termination; (b) in the case of the termination of this Agreement with respect to a

country pursuant to Section 15.2 or Section 15.3, all Licensed Products in the country subject to such termination; and (c) in the case of termination of this Agreement in its entirety, all Licensed Products in all countries in the Territory.

1.213“Third Party” means any Person other than Agenus or Gilead that is not an Affiliate of Agenus or of Gilead.

1.214“Third Party Claim” means any and all suits, claims, actions, proceedings, or demands brought by a Third Party.

1.216“Third Party Infringement Claim” has the meaning set forth in Section 11.4.1.

1.220“U.S. Co-Commercialization Agreement” has the meaning set forth in Section 6.2.

1.221“U.S. Co-Commercialization Negotiation Period” has the meaning set forth in Section 6.2.

1.222“U.S. Co-Commercialization Notice” has the meaning set forth in Section 6.2.

1.223“U.S. Co-Commercialization Option” has the meaning set forth in Section 6.2.

1.224“U.S. Development” means, with respect to the Profit-Share Product, Development activities intended to support the filing of an MAA (including any supplement or amendment thereto) for the Profit-Share Product in the U.S.

1.225“United States” or “U.S.” means the United States of America and all of its territories and possessions.

1.226“Upstream License Agreement” means any contract or agreement with a Third Party pursuant to which Agenus in-licenses or otherwise maintains Control of Patents, Know-How, or other intellectual property rights that constitute Agenus IP for purposes of this Agreement, including such Upstream License Agreements set forth on Schedule 13.2.15 (“Existing Upstream License Agreements”) and any Upstream License Agreements which become such pursuant to Section 8.6.

1.227“Valid Claim” means, (a) with respect to a pending application, [******]; and (b) with respect to an issued Patent, a claim of such patent that has not expired, lapsed, been cancelled, or abandoned, or been dedicated to the public, disclaimed, or held unenforceable, invalid, revoked, or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal has been or can be taken, including through opposition, reexamination, reissue, disclaimer, inter partes review, post grant procedures, or similar proceedings.

1.228“[******]” means a [******] of a [******] of an [******] and a [******] of an [******] that [******].

. Agenus hereby grants to Gilead an exclusive option, during the Option Period, to obtain an exclusive license, under the Agenus IP, to Develop, Manufacture, and Commercialize Licensed Products in the Field in the Territory on the terms and conditions provided in this Agreement (the “Option”).

2.2.1Development. Prior to the Option Effective Date, Agenus shall be solely responsible for the Development (and Manufacture, or having Manufactured, for the purposes thereof) of the Licensed Antibodies and the Licensed Products; provided, that Agenus shall use Commercially Reasonable Efforts to Develop the Licensed Antibodies and the Licensed Products and Manufacture or have Manufactured necessary quantities thereof in accordance with: (a) the Agenus Development Plan, as may be amended from time to time by mutual agreement of the Parties or to the extent required by Applicable Law or any relevant Regulatory Authority; (b) the Clinical Trial Criteria; and (c) the reasonable directions of the JSC. Subject to Section 2.2.5, all such Development and associated Manufacturing shall be [******]. The Agenus Development Plan shall remain in effect unless and until amended as provided herein. From the Effective Date until the Option Effective Date, the JSC shall review and discuss potential amendments to the Agenus Development Plan at least [******]. In addition, the Parties will agree upon an amendment to the Agenus Development Plan in order to ensure that such plan is designed to enable Agenus to, during the Option Period, provide Gilead with the Data Package with respect to the first completed Phase 1b Clinical Trial of an Initial Licensed Product which meets the Clinical Trial Criteria.

2.2.2Prosecution and Maintenance of Agenus Patents. Prior to the Option Effective Date and subject to Section 11.2.1, Agenus shall [******] Prosecute and Maintain the Agenus Patents [******].

2.2.3Information-Sharing. Prior to the Option Effective Date, at each meeting of the JSC or as otherwise agreed by the Parties, Agenus will provide the JSC with written reports or presentations summarizing its activities with respect to the Development and associated Manufacture of the Licensed Antibodies and the Licensed Products. Each report or presentation will cover such activities since the previous JSC meeting, including a summary of results, information, and data generated and any material developments and activities planned with respect to the Licensed Antibodies or the Licensed Products. Upon request by the JSC or by Gilead, Agenus will provide the JSC with such other then-existing information and such additional access to records with respect to the Licensed Antibodies and the Licensed Products as the JSC or Gilead may reasonably request, including the underlying information used to support such summaries.

2.2.5Supply of Licensed Products for Phase 2 Clinical Trial. During the Option Period, Gilead may request, by written notice to Agenus, that Agenus, either itself or through a mutually-acceptable Third Party contract manufacturer, Manufacture Initial Licensed Product for purposes of a Phase 2 Clinical Trial (as determined in Gilead’s reasonable discretion) to be conducted following the Option Effective Date. Following such request, and [******], Agenus shall [******], either itself or through a mutually-acceptable Third Party contract manufacturer, to Manufacture such supply. Gilead shall reimburse Agenus for the

[******]. Agenus shall, upon Gilead’s request, promptly terminate, or cause to be terminated, the Manufacture of supply (if any) by a Third Party contract manufacturer pursuant to this Section 2.2.5; provided, that Gilead shall reimburse Agenus for [******]. To the extent Manufacturing under this Section 2.2.5 is performed by Agenus (rather than a Third Party contract manufacturer), the terms on which Gilead will purchase such Initial Licensed Products will be [******]. All Initial License Product Manufactured pursuant to this Section 2.2.5 shall remain in the possession and control of Agenus unless and until the Option Effective Date occurs.

(a)Agenus shall provide Gilead with the Data Package with respect to the first completed Phase 1b Clinical Trial of an Initial Licensed Product which meets the Clinical Trial Criteria promptly following the completion of such Phase 1b Clinical Trial.

(c)Notwithstanding Section 2.3.2(b), from Gilead’s receipt of the Data Package until the expiration of the Option Period, Gilead may provide Agenus with written notice requesting then-existing additional information with respect to the Licensed Antibodies or applicable Licensed Products, or a discussion with Agenus representative(s) who have the relevant knowledge and information regarding the Licensed Antibodies or the applicable Licensed Products, reasonably required in order to understand such Data Package or to evaluate whether to exercise the Option (each, an “Information Request Notice”). Agenus shall use all reasonable efforts to provide such information or hold such discussion as promptly as practicable but in any event within [******] after receipt of such Information Request Notice. If the Information Request Notice is provided during the [******], to the extent that Agenus has not provided such information in any material respect or has failed to hold such discussion within the [******] period, Gilead shall notify Agenus thereof and the Option Period shall be extended by [******].

(a)Notwithstanding Section 2.3.1, [******] during the period from the Effective Date until the first completed Phase 1b Clinical Trial of an Initial Licensed Product which meets the Clinical Trial Criteria, Gilead may provide written notice to Agenus requesting a Data Package (each, a “Data Package Request Notice”). Promptly, but in any event within [******]following receipt of such Data Package Request Notice, Agenus shall deliver to Gilead such Data Package. Beginning upon receipt of the Data Package, Gilead shall have a period of [******] to review the Data Package (as such period may be extended in accordance with Section 2.3.2(b), the “Option Early Exercise Review Period”).

(b)From time to time during the Option Early Exercise Review Period, Gilead may provide Agenus with written notice requesting additional then-existing information with respect to the Licensed Antibodies or the applicable Licensed Products, or a discussion with Agenus representative(s) who have the relevant knowledge and information regarding the Licensed Antibodies or Licensed Products, reasonably required in order to understand such Data Package or to evaluate whether to exercise the Option (each, an “Early Exercise Comment Notice”), and Agenus will provide such information or hold such discussion as promptly as practicable but in any event within [******] after receipt of such Early Exercise Comment Notice. If an Early Exercise Comment Notice is provided during the first [******] of the Option Early Exercise Review Period, to the extent that Agenus has not provided such information in any material

respect or has failed to hold such discussion within the [******] period, Gilead shall notify Agenus thereof and the Option Early Exercise Review Period shall be extended by [******].

(c)Notwithstanding Section 2.3.2(b), if, following delivery of a Data Package Request Notice, Gilead has not exercised the Option within the Option Early Exercise Review Period applicable to such Data Package Request Notice, then Gilead may submit a new Data Package Request Notice, in which case Section 2.3.2(a) shall apply to such new Data Package Request Notice.

. Gilead may exercise the Option (the “Option Exercise”) at any time during the Option Period by providing written notice thereof (the “Option Exercise Notice ”) to Agenus. Gilead shall deliver, together the Option Exercise Notice, a notice to Agenus which identifies the filings, notices, applications, or other submissions, if any, under Antitrust Law which Gilead determines are necessary or advisable in connection with the Option Exercise (“Antitrust Filings”) and Agenus shall deliver an updated Schedule 13.2 as of the Option Exercise Date to the extent that Gilead has not received the Data Package as of such date. Gilead’s rights and obligations hereunder in connection with the Option Exercise (including any licenses to be granted in connection therewith) shall become effective only upon the Option Closing Date (the “Option Effective Date”). If no Option Exercise occurs pursuant to Section 2.4 within the Option Period, then Gilead shall have no further rights with respect to Licensed Antibodies and Licensed Products under this Agreement.

. As soon as reasonably practicable following date on which Gilead provides the Option Exercise Notice to Agenus in accordance with Section 2.4 (the “Option Exercise Date”) and in any event within [******] thereof, each of Agenus and Gilead shall prepare and submit any Antitrust Filings, if any, including any such required filings under the HSR Act and the rules promulgated thereunder, with respect to the Option Exercise. In connection with any such Antitrust Filings, the Parties shall furnish promptly to the United States Federal Trade Commission, the Antitrust Division of the United States Department of Justice, and any other applicable Governmental Authority any additional information requested within their authority under the HSR Act or other Antitrust Law, use reasonable efforts to obtain antitrust clearance for the transactions contemplated hereunder as soon as practicable with respect to the Option Exercise, and otherwise cooperate with each other in the governmental antitrust clearance process. [******] fees in connection with any filings under this Section 2.5, and [******] attorneys’ fees and other expenses in connection therewith.

2.6.1Option Exercise Closing. The closing of the transactions contemplated by this Agreement in connection with the Option Exercise (including any licenses to be granted in connection therewith) shall take place remotely via the electronic exchange of documents and signatures as soon as practical, but no later than the [******] following the date on which all of the conditions precedent set forth in Section 2.6.2 have been satisfied or waived by the applicable Party (other than Section 2.6.2(c), which can only be satisfied or waived at the closing), or at such other time and place as Agenus and Gilead may agree upon in writing (the “Option Closing Date”).

2.6.2Conditions to Option Effectiveness. The obligation of the Parties to consummate the transactions contemplated by this Agreement in connection with the Option Exercise (including any licenses to be granted in connection therewith) is subject to the satisfaction by each Party of the following conditions, any or all of which may be waived in whole or in part by the other Party in its sole discretion, subject to Applicable Law:

(a)the expiration or termination of all applicable waiting period(s) and any other required clearances under the Antitrust Filings, if any, including under the HSR Act;

(b)the representations and warranties made by such Party in Sections 13.1 and 13.2 (with respect to Agenus) and Sections 13.1 and 13.3 (with respect to Gilead) shall be true and correct in all material respects as of the Option Effective Date, as updated by any updated Schedule 13.2 that Agenus may deliver as of the Option Effective Date and, with respect to Agenus as such Party, Agenus shall have performed and complied in all material respects with the covenants set forth in Section 13.4.2; and

(c)the provision by each Party to the other Party of an officer’s certificate certifying the satisfaction of the condition in Section 2.6.2(b) with respect to such Party.

. Promptly following the Option Effective Date, Gilead shall provide to Agenus the initial Gilead Development Plan, including the initial Gilead Development Budget.

3.1.1Establishment; Responsibilities. Within [******] after the Effective Date, the Parties shall establish a joint steering committee (the “JSC”) as more fully described in this Section 3.1. The JSC shall serve as a forum to facilitate communications between the Parties and, to the extent provided in this Section 3.1, shall have review and decision-making responsibilities, as well as general oversight of the relevant activities, with respect to: (a) Development (and Manufacture, or having Manufactured, for the purposes thereof) of the Licensed Antibodies and the Licensed Products prior to the Option Effective Date; and (b) the Development and Commercialization of the Profit-Share Product during the Profit-Share Term. In particular, the JSC shall: (i) review and discuss potential amendments to the Agenus Development Plan in accordance with Section 2.2.1; (ii) request, receive, and review information and access to records with respect to the Licensed Antibodies and the Licensed Products prior to the Option Effective Date in accordance with Section 2.2.3; (iii) review, discuss, and approve any amendment to the Gilead Development Plan, including the Gilead Development Budget, in accordance with Section 4.2; (iv) adopt and approve the Commercialization Plan (including the Commercialization Budget), including any amendments thereto, in accordance with Section 6.1; and (v) review and discuss, from time to time, [******].

3.1.2Representatives. The JSC shall be comprised of [******] (or such other number of representatives as the Parties may mutually agree; provided, that Gilead and Agenus shall at all times have an equal number of representatives on the JSC) from each of Gilead and Agenus. Each representative of a Party shall have sufficient seniority and expertise to participate on the JSC as determined in such Party’s reasonable judgment. Gilead shall have the right to designate the chairperson of the JSC from among its [******] JSC representatives. Each Party may replace any or all of its representatives on the JSC at any time upon written notice to the other Party in accordance with Section 16.2. Each Party may, upon receiving the other Party’s prior written consent (not to be unreasonably withheld, conditioned, or delayed), invite non-JSC representatives of such Party and any Third Party to attend meetings of the JSC; provided, that any such non-JSC representative or Third Party is bound by obligations of confidentiality, non-disclosure, and non-use no less restrictive than those set forth in Article 12, and obligations as to ownership of inventions and data consistent with those set forth in this Agreement, prior to attending any such meeting.

3.1.3Meetings. The first scheduled meeting of the JSC shall be held no later than [******] after establishment of the JSC unless otherwise agreed by the Parties. After the first scheduled meeting of the JSC until the time at which the JSC is disbanded in accordance with Section 3.1.5, the JSC shall meet in person or telephonically at least [******], or more or less frequently as the Parties agree, on

such dates and at such places and times as provided herein or as the Parties shall agree; provided, that representatives of the JSC shall in any event meet at least [******] per Calendar Year in person. The representatives of the JSC may also convene or be consulted from time to time by means of telecommunications, video conferences, electronic mail, or correspondence, as deemed necessary or appropriate. Each Party shall bear all costs and expenses it incurs in regard to participating in all meetings of the JSC, including all travel and living expenses.

3.1.4Minutes. Gilead shall be responsible for preparing and circulating minutes of each meeting of the JSC, setting forth, inter alia, an overview of the discussions at the meeting. A draft of such minutes shall be circulated by Gilead to all representatives of the JSC within [******] after the applicable meeting. Such minutes shall be effective only after such minutes have been approved by both Parties in writing. Definitive minutes of all JSC meetings shall be approved and finalized no later than [******] after the meeting to which the minutes pertain.

3.1.5Decisions. Except as otherwise set forth in this Agreement, for matters over which the JSC has decision-making authority, all decisions of the JSC shall be made by consensus, with each Party having one (1) vote. Decisions of the JSC made at a meeting shall be recorded in the definitive minutes for such meeting approved by both Parties as set forth in Section 3.1.4. If the JSC cannot agree on any such matter, then either Party may, by providing written notice to the other Party, have such matter referred to the Executive Officers for resolution. If the Executive Officers are unable to resolve the matter within [******] (or such other longer time frame that the Executive Officers may otherwise agree upon) after the matter is referred to them in accordance with this Section 3.1.5 , then: [******]; provided, that, [******] shall not have the right to: (i) make a decision that is stated to require the mutual agreement or mutual consent of the Parties; (ii) amend, modify, interpret, or waive the terms of this Agreement or the U.S. Co-Commercialization Agreement, or otherwise act in contravention of the terms of this Agreement; (iii) resolve any dispute regarding whether a Milestone Event or a Sales Milestone Event set forth herein has been achieved; or (iv) require [******] to perform any act that it reasonably believes to be inconsistent with Applicable Law.

3.1.6Disbandment. The JSC shall remain in effect from the date on which it is established in accordance with Section 3.1.1 and shall automatically disband on the earlier of: (a) the Profit-Share Option Exercise Deadline, if Agenus does not exercise the Profit-Share Option in accordance with Section 9.3.2; or (b) the expiration of the Profit-Share Term, if Agenus exercises the Profit-Share Option in accordance with Section 9.3.2.

. The JSC may, at any time that it deems necessary or appropriate, establish additional joint committees (including, e.g., [******]) and delegate such of its responsibilities as it determines appropriate to such joint committees. Any such joint committees shall automatically be disbanded upon the disbandment of the JSC in accordance with Section 3.1.6.

. Subject to the terms and conditions of this Agreement, Gilead shall have the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees, or other Third Parties, to Develop the Licensed Products in the Field in the Territory. Subject to Section 9.3, all such Development shall be at [******].

. During the Profit-Share Term: (a) the JSC shall review and discuss potential amendments to the Gilead Development Plan, including the Gilead Development Budget, at least [******]; and (b) subject to Section 3.1.5, the JSC shall have the authority to approve any amendment to the Gilead Development Plan, including the Gilead Development Budget.

. From the expiration of the Profit-Share Term, if any, and continuing until the date on which Gilead has submitted an MAA to the applicable Regulatory Authority for [******] Licensed Product [******], Gilead shall submit to Agenus, [******], a written report with respect to the Licensed Products summarizing: [******].

(a)Prior to the Option Effective Date, Agenus shall have the sole right (and shall solely control, at its discretion but subject to JSC input and approval), itself or with or through its Affiliates or other Third Parties to prepare, and submit to applicable Regulatory Authorities, all Regulatory Materials, for Licensed Products.

(b)From and after the Option Effective Date, and subject to the terms and conditions of this Agreement, Gilead shall have the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees, or other Third Parties, to: (i) prepare, and submit to applicable Regulatory Authorities, all Regulatory Materials for Licensed Products; and (ii) obtain and maintain all Regulatory Approvals for Licensed Products.

5.1.2Communications with Regulatory Authorities. For clarity and without limiting Section 5.1.1:

(a)Prior to the Option Effective Date, (i) Agenus shall have the exclusive right to correspond or communicate with Regulatory Authorities regarding the Licensed Products, (ii) unless required by Applicable Law, Gilead, its Affiliates, and its permitted subcontractors shall not correspond or communicate with Regulatory Authorities regarding any Licensed Product without first obtaining Agenus’ prior written consent, and (iii) if Gilead, its Affiliates, or its permitted subcontractors receive any correspondence or other communication from a Regulatory Authority regarding a Licensed Product, Gilead shall provide Agenus with access to or copies of all such material written or electronic correspondence promptly after its receipt.

(b)From and after the Option Effective Date, (i) Gilead shall have the exclusive right to correspond or communicate with Regulatory Authorities regarding the Licensed Products, (ii) unless required by Applicable Law, Agenus, its Affiliates, and its permitted subcontractors shall not correspond or communicate with Regulatory Authorities regarding any Licensed Product without first obtaining Gilead’s prior written consent, and (iii) if Agenus, its Affiliates, or its permitted subcontractors receive any correspondence or other communication from a Regulatory Authority regarding a Licensed Product, Agenus shall provide Gilead with access to or copies of all such material written or electronic correspondence promptly after its receipt.

5.1.3Agenus Support. From and after the Option Effective Date, Agenus shall [******] to support Gilead as may be reasonably requested by Gilead from time to time in connection with Gilead’s preparation, submission to Regulatory Authorities and maintenance of Regulatory Materials for Licensed Products, including, upon Gilead’s reasonable request, attending meetings with Regulatory Authorities regarding any Licensed Product.

5.2.1Pre-Option Exercise Regulatory Materials. Agenus shall solely own any and all Regulatory Materials for the Licensed Products made, generated or filed prior to the Option Effective Date (the “Existing Regulatory Materials”). Except to the extent notified otherwise in writing by Gilead, after the Option Effective Date, Agenus shall assign and transfer (and hereby does assign and transfer), or cause to be assigned and transferred to the extent not owned by Agenus, to Gilead (or its designee), no later than [******] after the Option Effective Date any and all Existing Regulatory Materials, including providing true, accurate, and complete hard or electronic copies thereof to Gilead. From and after such assignment and transfer, Gilead (or its designee) shall have the sole right, in its sole discretion, to file, maintain, and hold title to all Existing Regulatory Materials.

5.2.2New Regulatory Materials. All Regulatory Materials generated or arising from or in connection with activities under this Agreement after the Option Effective Date with respect to Licensed Products shall be owned by and held in the name of Gilead or its designee, and, except for Existing Regulatory Materials (which are addressed in Section 5.2.1), and any such Regulatory Materials issued in the name of Agenus, its Affiliates or contractors shall promptly following the Option Effective Date be assigned by Agenus to Gilead or its designee to the extent permitted by Applicable Law or, in the event assignment is not permitted under Applicable Law, held in trust for, or for the sole benefit of, Gilead or its designee.

5.3.1From and after the Option Effective Date and prior to the time at which Regulatory Materials are transferred and assigned to Gilead or its designee, or in the event of failure to transfer and assign any Regulatory Materials to Gilead or its designee, as required by Section 5.2.1 or Section 5.2.2, Gilead and its designees shall have, and Agenus (on behalf of itself and its Affiliates) hereby grants to Gilead and its designees, access and a right of reference (without any further action required on the part of Agenus, its Affiliates or contractors, whose authorization to file this consent with any Regulatory Authority is hereby granted) to all such Regulatory Materials and all data contained or referenced therein for Gilead and its designees to exercise its rights and perform its obligations under this Agreement with respect to Licensed Products. In all cases, from and after the Option Effective Date, Gilead and its designees shall have access to all data contained or referenced in all such Regulatory Materials, and Agenus shall ensure that Gilead and its designees are afforded such access.

5.3.2Upon transfer and assignment of the Existing Regulatory Materials and the data contained or referenced therein to Gilead or its designee in accordance with Section 5.2.1, Gilead shall grant and hereby grants to Agenus and its designees a right of reference (without any further action required on the part of Gilead, its Affiliates or contractors, whose authorization to file this right of reference with any Regulatory Authority is hereby granted) to any INDs transferred and assigned to Gilead as an Existing Regulatory Material and all data contained or referenced therein, solely for Agenus and its designees to Develop and seek and maintain Regulatory Approvals of [******].

. Subject to the terms and conditions of this Agreement, from and after the Option Effective Date, Gilead shall have, subject to Section 6.2, the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees, or other Third Parties, to Commercialize the Licensed Products in the Field in the Territory. Subject to Section 9.3, all such Commercialization shall be at [******]. During the Profit-Share Term, such Commercialization activities in the U.S. shall be conducted in accordance with the Commercialization Plan and the Commercialization Budget, which shall be adopted and approved (including any amendments thereto), from time to time by the JSC.

. If Agenus exercises the Profit-Share Option, it shall have the option (the “U.S. Co-Commercialization Option”), exercisable by providing written notice to Gilead (the “U.S. Co-Commercialization Notice”) in the Profit-Share Option Exercise Notice, to perform certain Commercialization-related activities with respect to the Profit-Share Product in the United States as set forth in Schedule 6.2. If Agenus does not exercise the U.S. Co-Commercialization Option in accordance with this Section 6.2, then such option will be deemed irrevocably waived. If Agenus exercises the U.S. Co-Commercialization Option, the Parties shall negotiate in good-faith for up to [******] Gilead’s receipt of the U.S. Co-Commercialization Notice (the “U.S. Co-Commercialization Negotiation Period”) the terms of a definitive agreement addressing such activities, which agreement will include the terms set forth in Schedule 6.2 (the “U.S. Co-Commercialization Agreement”) and such other mutually agreed terms and conditions as are customary for agreements of such type which are consistent with the terms and conditions of this Agreement, including Schedule 6.2. The U.S. Co-Commercialization Agreement shall include: [******].

7.1.1Subject to the terms and conditions of this Agreement, prior to the Option Effective Date, Agenus shall have the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees, or other Third Parties, to Manufacture the Licensed Products in the Field in the Territory. Subject to Section 2.2.5, prior to the Option Effective Date, all such Manufacturing shall be [******].

7.1.2Subject to the terms and conditions of this Agreement, from and after the Option Effective Date, Gilead shall have the sole right (and shall solely control, at its discretion), itself or with or through its Affiliates, Sublicensees, or other Third Parties, to Manufacture the Licensed Products in the Field in the Territory. Subject to Section 9.3, from and after the Option Effective Date, all such Manufacturing shall be [******].

. At the election of Gilead exercisable by written notice to Agenus within [******] of the Option Effective Date, and subject to any manufacturing capacity constraints that Agenus may have at the time of such request, the Parties shall conduct good-faith discussions regarding the terms of a supply agreement (and a corresponding quality agreement with customary terms and conditions) pursuant to which Agenus would supply the Licensed Products to Gilead for its Clinical Trials (the “Supply Agreement”). [******]. In addition, the Supply Agreement shall otherwise include mutually agreed terms as are customary for agreements of such type.

. No later than [******], the Parties shall enter into a pharmacovigilance agreement in customary form in order to, among other things, coordinate safety matters and share of safety information with respect to the Licensed Products.

. From and after the Option Effective Date, Agenus shall, and shall cause its Affiliates to, cooperate with Gilead and its designees and provide reasonable assistance to Gilead and its designees to transition Development and Manufacturing activities with respect to Initial Licensed Products to Gilead and its designees to the extent reasonably requested by Gilead, including by: (a) providing Gilead and its designees reasonable assistance with respect to Development, regulatory, and Manufacturing transition matters related to the Initial Licensed Products; and (b) providing Gilead and its designees with reasonable access by teleconference or in‑person (as requested by Gilead) to Agenus personnel (and personnel of its Affiliates and Third Party contractors) involved in Development, regulatory, or Manufacturing matters related to the Initial Licensed Products to assist with the transition and answer questions related to the Initial Licensed Products. Agenus shall provide the assistance described in this Article 8, with qualified personnel and at Gilead’s reasonable request, [******] (the “Transition Period”); provided, that Agenus shall, and shall cause its Affiliates to, complete the activities assigned to, or otherwise contemplated to be completed by, Agenus under the Tech Transfer Plan which have not been completed as of the expiration of the Transition Period, and shall cooperate in good faith with Gilead and its designees and provide reasonable assistance to Gilead and its designees after expiration of the Transition Period to address any issues arising out of or not addressed by the transition activities contemplated by this Section 8.1, which issues are materially and adversely impacting Gilead’s ability to assume responsibility for the Development and Manufacture of the Initial Licensed Products in accordance with this Agreement.

. Without limiting the provisions of Section 8.1, as soon as reasonably practicable following the Option Exercise Date (but in no event later than [******] following the Option Exercise Date), the Parties shall agree on and commence performance of a plan (the “Tech Transfer Plan”), pursuant to which Agenus shall promptly, following the Option Effective Date and the Tech Transfer Plan’s agreement and execution, disclose to Gilead and its designees in English, including by providing hard or electronic copies thereof, [******].

. Without limiting the provisions of Section 8.1, upon Gilead’s written request and at no additional cost to Gilead, Agenus shall promptly following the Option Effective Date assign and transfer to Gilead or its designee and deliver to Gilead or its designee, at a location to be specified by Gilead, the inventory of the Licensed Products held at such time by or on behalf of Agenus or its Affiliates (including any such inventory held at any contract manufacturer or any other location) (the “Transferred Inventory”), along with all applicable manufacturing, GMP and shelf-life information in accordance with the Tech Transfer Plan.

. Without limiting the other provisions of Article 8, as soon as reasonably practicable following the Option Effective Date (but in no event later than as required under the Tech Transfer Plan), Agenus shall transfer, and thereafter continue, during the Transition Period as may be reasonably requested by Gilead from time to time, the transfer (from Agenus, its Affiliates, or its Third Party contract manufacturers) to Gilead and its designees copies in English (in writing or in an electronic format) of [******] as of the Option Effective Date that is [******] to the Manufacture of the Licensed Products, in order to enable Gilead and its designees to Manufacture the Licensed Products, including, if desired by Gilead, to replicate the process employed by or on behalf of Agenus prior to the Option Effective Date to Manufacture the Licensed Products. Such transfers shall be in accordance with the Tech Transfer Plan in which the Parties have identified [******] required for Manufacture, or [******]

for the Development and Manufacture of the Licensed Products; provided, that, if Gilead reasonably believes that any materials which are not identified in the Tech Transfer Plan are [******] for the Manufacture, or are [******] for the Development or Manufacture, of the Licensed Products (but excluding [******]), then Agenus shall cooperate in good faith with Gilead to provide such materials to Gilead. In addition, at the reasonable request of Gilead from time to time, Agenus shall make its employees and consultants (including personnel of its Affiliates and Third Party contract manufacturers) available to Gilead and its designees to provide reasonable consultation and technical assistance in order to ensure an orderly transition of the Manufacturing technology and operations to Gilead and its designees and to assist Gilead and its designees in the Manufacture of the Licensed Products. [******].

. After the Option Effective Date, Agenus shall, or shall cause its Affiliates to, as applicable, to the extent legally permissible (provided, that, to the extent consent is required from the relevant counterparty, Agenus shall, or shall cause its Affiliates to, as applicable, [******]): (a) assign to Gilead or its designee any or all (as designated by Gilead) Development and Manufacturing Agreements; or (b) assist Gilead or its Affiliate in entering into new agreements directly with the counterparties to any or all Development and Manufacturing Agreements to cover the subject matter of such Development and Manufacturing Agreements, as applicable, in each case ((a) and (b)), to the extent requested by Gilead in writing. If any Development and Manufacturing Agreement is assigned to Gilead, Agenus shall be solely responsible for, and shall indemnify and hold harmless Gilead and all other Gilead Indemnitees from and against any costs and other Damages arising from, or relating to, any such Development and Manufacturing Agreement as a result of, or in connection with, events or occurrences prior to the date of such assignment (including any payments that accrued prior to the date of such assignment but which do not become payable until after the date of such assignment).

. In the event that after the Option Effective Date Agenus enters into a contract or agreement with a Third Party pursuant to which Agenus in-licenses or otherwise acquires Control of any Patents, Know-How, or other intellectual property rights that would constitute Agenus IP for purposes of this Agreement, then Agenus shall promptly provide Gilead with notice and a copy of the applicable license or other contract or agreement with the Third Party. Within [******] following receipt of such notice, Gilead shall decide, in its sole discretion, whether or not to accept such Patents, Know-How, or other intellectual property as Agenus IP licensed under this Agreement and provide Agenus written notice of such decision. In the event of acceptance, such Patents, Know-How, or other intellectual property shall constitute Agenus IP licensed to Gilead under this Agreement, such agreement shall thereafter be included within the definition of Upstream License Agreements, and [******] shall be responsible for any payments arising thereunder [******] (provided, that, [******]). In the event that Gilead does not accept such Third Party agreement as an Upstream License Agreement (including by failing to respond within such [******] period), Gilead and its Affiliates shall have no obligations with respect to such Third Party agreement and such Patents, Know-How or other intellectual property shall not constitute Agenus IP licensed to Gilead hereunder.

. No later than [******] after the Effective Date, Gilead shall pay to Agenus a one (1)-time, non-refundable, and non-creditable payment of [******] in immediately available funds by wire transfer, in accordance with wire instructions to be provided in writing by Agenus to Gilead on or before the Effective Date.

. No later than [******] after the Option Effective Date, Gilead shall pay to Agenus a one (1)-time, non-refundable, and non-creditable payment of [******] in immediately available

funds by wire transfer, in accordance with wire instructions to be provided in writing by Agenus to Gilead no later than [******] after the Option Effective Date.

9.3.1General; Limitation. From and after the Option Effective Date, Agenus shall have the option, exercisable by written notice provided to Gilead in accordance with Section 9.3.2 at any time until [******] following the later of: (a) the Option Effective Date; and (b) [******] (such end date, the “Profit-Share Option Exercise Deadline” and such option, the “Profit-Share Option”), to share in Development Costs and Profit (Loss) (the “Profit-Share”) with respect to the Profit-Share Product in the U.S. Agenus may only exercise one (1) Profit-Share Option under this Agreement and the Option and License Agreement (AGEN2373). Once Agenus exercises the Profit-Share Option under one (1) of the Option and License Agreements, Agenus’s right to exercise the Profit-Share Option under the other Option and License Agreement shall irrevocably terminate. In addition, if Agenus exercises its Profit-Share Option under this Agreement, then from and after Agenus’ delivery of the Profit-Share Opt-Out Notice in accordance with Section 9.3.5(a) or Gilead’s delivery of the Profit-Share termination notice in accordance with Section 9.3.5(b), as applicable, Agenus’ right to exercise the Profit-Share Option under the Option and License Agreement (AGEN2373) shall irrevocably terminate. [******].

9.3.2Exercise. In the event that Agenus wishes to exercise the Profit-Share Option, it shall deliver written notice to Gilead of its election (the “Profit-Share Option Exercise Notice”) no later than the Profit-Share Option Exercise Deadline. If Agenus does not deliver the Profit-Share Option Exercise Notice in accordance with this Section 9.3.2, then Agenus’s right to exercise the Profit-Share Option will be deemed irrevocably waived.

9.3.3Effects of Exercise . If the Profit-Share Option is exercised, then, during the Profit-Share Term:

(a)The Parties shall share responsibility for Development Costs as follows: (i) Gilead shall bear [******] percent ([******]%) of such Development Costs; and (ii) Agenus shall bear [******] percent ([******]%) of such Development Costs;

(b)The Parties shall share Profit (Loss) as follows: (i) Gilead shall bear (and be entitled to) [******] percent ([******]%) of Profit (Loss); and (ii) Agenus shall bear (and be entitled to) [******] percent ([******]%) of Profit (Loss); and

(c)Agenus shall be entitled to receive Milestone Payments, Sales Milestone Payments, and royalty payments with respect to such Profit-Share Product in accordance with Section 9.6, Section 9.7, and Section 9.8.

(a)In the event that, during the Profit-Share Term and prior to the date on which an MAA for the first Profit-Share Product is submitted in the United States, the Gilead Development Budget is amended in accordance with Section 4.2 such that the amount of Development Costs for which Agenus is responsible pursuant to Section 9.3.3(a) pursuant to the Gilead Development Budget in effect immediately following such amendment exceeds [******] percent ([******]%) of the amount of Development Costs for which Agenus was responsible pursuant to the Gilead Development Budget in effect immediately prior to such amendment (each such amendment, a “Material Amendment” and such amount of excess Development Costs, “Additional Development Costs”), then [******].

(a)Agenus-Opt-Out. In the event that Agenus has exercised the Profit-Share Option in accordance with Section 9.3.2, it shall have the one (1)-time option to elect to irrevocably opt-out of the Profit-Share (the “Profit-Share Opt-Out Option”) in accordance with this Section 9.3.5(a). The Profit-Share Opt-Out Option shall be exercisable by Agenus at any time from [******] until [******] (the “Profit-Share Opt-Out Option Exercise Deadline”). In the event that Agenus wishes to exercise the Profit-Share Opt-Out Option, it shall deliver written notice to Gilead of its election (the “Profit-Share Opt-Out Notice”) no later than the Profit-Share Opt-Out Option Exercise Deadline. If Agenus does not deliver the Profit-Share Opt-Out Notice in accordance with this Section 9.3.5(a), then Agenus’s right to exercise the Profit-Share Opt-Out Option will be deemed irrevocably waived.

(b)Gilead Termination. Gilead may terminate the Profit-Share in accordance with this Section 9.3.5(b) if, at any time during the Profit-Share Term, Agenus fails to reimburse Gilead for its share of Agenus Development Costs or Profit (Loss) in accordance with Section 9.4 or Section 9.5.3, as applicable; provided, that Agenus has not cured such failure within [******] after the date on which Gilead provides written notice to Agenus of such failure, which notice shall describe such failure in reasonable detail and shall state Gilead’s intention to terminate the Profit-Share. Any such termination of the Profit-Share under this Section 9.3.5(b) shall become effective at the end of the [******] period (the “Profit-Share Termination Effective Date”), unless Agenus has cured such failure prior to the expiration of such [******] period.

(c)Effects of Agenus Opt-Out or Gilead Termination. From and after the Profit-Share Opt-Out Effective Date or the Profit-Share Termination Effective Date, as applicable, with respect to a Profit-Share Product:

(2)Any Milestone Payments or Sales Milestone Payments, in each case, that would have become due and payable during the Profit-Share Term with respect to the Profit-Share Product if such Profit-Share Product were a Royalty-Bearing Product will be deemed irrevocably waived;

(3)The U.S. Co-Commercialization Agreement (if then in effect) shall terminate in accordance with its terms; and

(4)Gilead shall promptly invoice Agenus for any Agenus Development Costs or Profit (Loss) incurred prior to the Profit-Share Opt-Out Effective Date or Profit-Share Termination Effective Date (as applicable) which have not been reimbursed by Agenus to Gilead in accordance with Section 9.4 or Section 9.5.3, as applicable (the “Outstanding Profit-Share Costs”), and Agenus will reimburse Gilead for the Outstanding Profit-Share Costs within [******] of receipt of such invoice; provided, that if Agenus fails to reimburse Gilead for the Outstanding Profit-Share Costs within such [******] period, then Gilead shall have the right, in its sole discretion, to deduct [******] any Outstanding Profit-Share Costs which have not been reimbursed by Agenus from [******]. For clarity, any liabilities or obligations of Agenus, including its obligation to pay a portion of Agenus Development Costs in accordance with Section 9.3.3(a) or a portion of Profit (Loss) in accordance with Section 9.3.3(b), which have accrued prior to the Profit-Share Opt-Out Effective Date or the Profit-Share Termination Effective

Date, as applicable, shall survive the exercise of the Profit-Share Opt-Out Option or the Profit-Share Termination Effective Date, as applicable.

(5)If, as of the Profit-Share Termination Effective Date, any [******] have not been offset by Gilead in accordance with Section 9.3.4(b), such [******] shall become due and payable no later than [******].

. Within [******] following the last day of each [******] during the Profit-Share Term, Gilead will provide to Agenus: (a) an expense report detailing all Development Costs incurred for the Profit-Share Product during such [******]; and (b) an invoice for the portion of such Development Costs payable by Agenus under Section 9.3.3(a) (the “Agenus Development Costs”) for such [******]. Agenus will reimburse Gilead for its share of such Agenus Development Costs for such [******] within [******] of receipt of each such invoice.

9.5.1During the Profit-Share Term, following the First Commercial Sale of the Profit-Share Product, Agenus shall furnish to Gilead a written report for each [******] showing the Operating Expenses incurred by Agenus with respect to the U.S. during the reporting [******]. Such reports shall be due no later than [******] following the end of each [******].

9.5.2Gilead shall furnish to Agenus a written report for each [******] showing the amount and calculation of the Profit (Loss) payable under this Agreement for such [******] in sufficient detail to allow Agenus to verify the amount of Profit (Loss) paid by Gilead with respect to such [******] Quarter, including the total gross amount invoiced for the Profit-Share Product sold in the U.S., the Net Sales of the Profit-Share Product in the U.S., COGS with respect to the Profit-Share Product for the U.S., and the Operating Expenses incurred by each of Gilead and Agenus with respect to the U.S. Such reports shall be due no later than [******] following the end of each [******].

9.5.3Gilead shall perform a reconciliation, as may be further detailed in the U.S. Co-Commercialization Agreement, to ensure that each Party bears and receives its share of Profit (Loss) as set forth in Section 9.3.3(b). Profit (Loss) shown to have accrued by each report provided under Section 9.5.2 and, subject to prompt resolution of any good faith dispute as to the accuracy of such reconciliation, Gilead’s reconciliation shall be due and payable within [******] of the date such report is due. If the Profit (Loss) for a [******] is negative, Gilead shall submit an invoice to Agenus for its share of such Profit (Loss). Agenus shall pay such invoice within [******] of receipt.

9.5.4The terms of this Agreement which are relevant for the purposes of determining and allocating Development Costs and Profit (Loss), including the applicable defined terms in Article 1 and payment and reconciliation mechanisms, may be amended in Gilead’s reasonable discretion during the U.S. Co-Commercialization Negotiation Period solely to ensure that such terms comply with Accounting Standards then in effect; provided, that: (a) Gilead provides any such proposed amendments to Agenus [******]; and (b) such proposed amendments [******].

9.6.1Milestones. Subject to the terms of this Section 9.6.1, Section 9.6.2, and Section 9.10.1, Gilead shall pay the applicable amount set forth in the table below in this Section 9.6.1 associated with each milestone event described below (each event, a “Milestone Event” and each payment, a “Milestone Payment”) with respect to the first (and only the first) Royalty-Bearing Product or Profit-Share Product, as applicable, to achieve such Milestone Event under this Agreement:



Development Milestone Event	Development Milestone Payment – Royalty-Bearing Product	Development Milestone Payment – Profit-Share Product
(a)[******]	[******]	[******]
(b)[******]	[******]	[******]
(c)[******]	[******]	[******]
(d)[******]	[******]	[******]
Regulatory Milestone Event	Regulatory Milestone Payment – Royalty-Bearing Product	Regulatory Milestone Payment – Profit-Share Product
(e)[******]	[******]	[******]
(f)[******]	[******]	[******]
(g)[******]	[******]	[******]

Each Milestone Payment shall be non-refundable, non-creditable, and payable a maximum of one (1) time as set forth in the table above, regardless of the number of Royalty-Bearing Products or Profit-Share Products, as applicable, which achieve the applicable Milestone Event (i.e., a maximum of [******] Milestone Payments may be made pursuant to this Section 9.6.1 with respect to Royalty-Bearing Products and a maximum of [******] Milestone Payments may be made pursuant to this Section 9.6.1 with respect to Profit-Share Products), and no Milestone Payment shall be due hereunder for subsequent or repeated achievement of any such Milestone Event, including where Milestone Event is first achieved by a Royalty-Bearing Product and is subsequently achieved by a Profit-Share Product (and vice versa).

Subject to Section 9.3.5(c)(2), upon the achievement of any Milestone Event listed in Section [******] above, any of the Milestone Event(s) listed in such Sections: (i) which are listed earlier in the table above than the achieved Milestone Event; and (ii) for which the applicable Milestone Payment(s) has not been previously paid, shall become due and payable together with the Milestone Payment due in connection with such achieved Milestone Event; provided, that if the achieved Milestone Event is the Milestone Event listed in Section [******] above, the Milestone Payment due in connection with the achievement of the Milestone Event listed in Section [******] shall not become due and payable together with the Milestone Payment due in connection with such achieved Milestone Event. If the Milestone Event listed in Section [******] above is achieved prior to the achievement of the Milestone Event listed in Section [******] above, then the Milestone Payment corresponding to the Milestone Event listed in Section [******] above shall become due and payable together with the Milestone Payment due in connection with the achievement of the Milestone Event listed in Section [******] above.

Further, if a [******] for a [******] does not constitute a [******] at the time of its [******], then subject to the other terms of this Section 9.6.1, such [******] shall be deemed a [******] and the Milestone Event listed in Section [******] or Section [******], as applicable, for such Indication shall be deemed achieved (to the extent not previously achieved) on the [******] for such [******].

For the avoidance of doubt, the maximum amount payable by Gilead pursuant to this Section 9.6.1 is [******] (with respect to Royalty-Bearing Products) or [******] (with respect to Profit-Share Products), as applicable, assuming that each Milestone Event in this Section 9.6.1 were achieved, but in no event shall the aggregate Milestone Payment due in connection with this Section 9.6.1 exceed [******].

(a)In the event that Gilead, its Affiliates, or its Sublicensees under this Agreement achieves a Milestone Event, it shall notify Agenus thereof within [******] of such achievement. Following Agenus’s receipt of notice from Gilead that Gilead has achieved a Milestone Event, Agenus shall invoice Gilead for the applicable Milestone Payment, and Gilead shall pay such Milestone Payment within [******] after receipt of such invoice.

(b)In the event that Agenus or its Affiliates achieves a Milestone Event, Agenus shall notify Gilead thereof within [******] of such achievement and invoice Gilead for the applicable Milestone Payment, and Gilead, subject to prompt resolution of any good faith dispute as to whether such Milestone Event has been achieved, shall pay such Milestone Payment within [******] after receipt of such invoice.

9.7.1Sales Milestones. Subject to the terms of this Section 9.7.1 and Section 9.10.2(b), Gilead shall notify Agenus within [******] after the end of the [******] during which a given milestone event described below in this Section 9.7.1 (each, a “Sales Milestone Event”) was first achieved by Gilead under this Agreement, and Gilead shall thereafter pay the applicable amounts set forth below associated with the applicable Sales Milestone Event in accordance with Section 9.7.2 (each, a “Sales Milestone Payment”):


Sales Milestone Event	Sales Milestone Payment
(a)[******]	[******]
(b)[******]	[******]
(c)[******]	[******]
(d)[******]	[******]

Each Sales Milestone Payment shall be non-refundable, non-creditable, and payable a maximum of one (1) time as set forth in the table above, regardless of the number of times the applicable Sales Milestone Event was achieved (i.e., a maximum of [******] Sales Milestone Payments may be made pursuant to this Section 9.7.1), and no Sales Milestone Payment shall be due hereunder for subsequent or repeated achievement of any such Sales Milestone Event. Upon achievement of any Sales Milestone Event listed in [******] above, any previously listed Sales Milestone Event for which the applicable Milestone Payment has not been paid shall be due together with the Milestone Payment due in connection with such achieved Sales Milestone Event. For the avoidance of doubt, the maximum amount payable by Gilead pursuant to this Section 9.7.1 is [******], assuming that each Sales Milestone Event in this Section 9.7.1 were achieved. [******].

9.7.2Invoice and Payment of Sales Milestone Payments. Following Agenus’s receipt of notice from Gilead that Gilead has achieved a Sales Milestone Event, Agenus shall invoice Gilead for the applicable Sales Milestone Payment, and Gilead shall pay such Sales Milestone Payment within [******] after receipt of the invoice therefor.

9.8.1Royalty Rates. Subject to the terms of this Section 9.8.1 and Section 9.10.2(b), Gilead shall pay Agenus royalties on Annual Net Sales in the Royalty Territory, on a Licensed Product-by-Licensed Product basis, during the applicable Royalty Term, equal to the following portions of Annual Net Sales of the applicable Licensed Product multiplied by the applicable royalty rate set forth below for such portion of Annual Net Sales in the Royalty Territory during the applicable Royalty Term for each such

Licensed Product. For clarity, the royalties (and royalty tiers) shall be calculated separately on a Licensed Product-by-Licensed Product basis.


Portion of Annual Net Sales in the Royalty Territory for a given Licensed Product in a given Calendar Year	Royalty Rate
i.[******]	[******]
ii.[******]	[******]
iii.[******]	[******]
iv.[******]	[******]

The applicable royalty rate set forth in the table above shall apply only to that portion of the Annual Net Sales in the Royalty Territory of a given Licensed Product during a given Calendar Year that falls within the indicated range. [******].

9.8.2Royalty Term. Gilead’s royalty obligations to Agenus under Section 9.8.1 shall apply, on a Licensed Product-by-Licensed Product and country-by-country basis, only during the applicable Royalty Term for such Licensed Product in such country. Following the expiration of the applicable Royalty Term for a given Licensed Product in a given country: (a) no further royalties shall be payable with respect to sales of such Licensed Product in such country; and (b) the license granted to Gilead under this Agreement with respect to such Licensed Product in such country shall become fully paid-up, perpetual, irrevocable, and royalty-free in accordance with Section 15.1.2(b)(1).

. Starting on the date of First Commercial Sale of a Licensed Product in the Territory, Gilead shall furnish to Agenus a [******] written report for each subsequent [******] showing the Net Sales of all Licensed Products and the royalty payments due to Agenus on such sales. Each such royalty report shall be due within [******] after the end of the relevant [******]. Each royalty report shall describe [******]. Within [******] following the delivery of the applicable [******] report, Agenus shall invoice Gilead for the royalties due to Agenus with respect to Net

Sales for such [******] as set forth in such royalty report and Gilead shall pay such amounts to Agenus within [******] following Gilead’s receipt of such invoice .

9.10.1Currency. All payments hereunder shall be made in Dollars by wire transfer to a bank designated in writing by the Payee no later than [******] prior to the date by which the applicable payment must be made. Conversion of sales recorded in local currencies to Dollars shall be performed in compliance with Accounting Standards and the Payor’s normal practices used to prepare its audited financial statements.

(a)Generally. Except as set forth in this Section 9.10.2, the Payee shall be liable for all income and other taxes (including interest) (“Taxes”) imposed upon any payments made by the Payor to Payee under this Agreement (“Agreement Payments”). The amounts set forth herein are exclusive of all applicable sales or use, goods and services, value added, consumption or other similar fees or taxes (“Transfer Taxes”) arising on the Agreement Payments, and the Payor shall be responsible for and pay any such Transfer Taxes imposed on it with respect to the Agreement Payments due to the Payee hereunder.

(b)Tax Withholding. If Applicable Law requires the withholding of Taxes, the Payor shall subtract the amount thereof from the Agreement Payments and remit such withheld amount to the relevant Governmental Authority in a timely manner; provided, however, that before making such withholding, the Payor shall use reasonable efforts to give the Payee notice of the intention to make such withholding. For the avoidance of doubt, Payor’s remittance of such withheld Taxes, together with payment to the Payee of the remaining Agreement Payments, shall constitute Payor’s full satisfaction of Agreement Payments under this Agreement. The Payor shall promptly (as available) submit to the Payee appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time. The Payor shall provide the Payee reasonable assistance in establishing entitlement to a reduction to, or elimination of, such withholding of Taxes under Applicable Law, including under the benefit of any present or future treaty against double taxation, and the Payor shall provide the Payee with reasonable assistance in seeking refund of such withheld Taxes. Notwithstanding the foregoing, if, as a result of Payor (i) assigning this Agreement, (ii) extending its rights or obligations pursuant to Section 16.16, or (iii) changing its domicile, additional Taxes become due that would not have otherwise been due hereunder with respect to Agreement Payments, Payor shall be responsible for all such additional withholding Taxes and shall pay Payee such amounts as are necessary to ensure that Payee receives the same amount as it would have received had no such assignment or change in domicile been made. [******].

(c)Tax Cooperation. The Parties shall cooperate with respect to all documentation required by any taxing authority or reasonably requested by either Party to secure a reduction in the rate of applicable withholding taxes.

. Each Party shall keep complete, true, and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including with respect to Gilead, its Affiliates, and cause its Sublicensees, in relation to Net Sales, royalties, Milestone Payments, Sales Milestone Payments, Development Costs, and Profit (Loss). Each Party shall keep such books and records for at least [******] following the Calendar Year to which they pertain or for such longer period of time as required under any Applicable Law.

9.11.2Audit Rights. Subject to the other terms of this Section 9.11.2, during the Term, at the request of a Party (the “Auditing Party”), which shall not be made more frequently than [******] per

[******], upon at least [******] prior written notice from the Auditing Party, and at the expense of the Auditing Party, the other Party (the “Audited Party”) shall permit an independent, nationally-recognized certified public accountant selected by the Auditing Party and reasonably acceptable to the Audited Party (the “Auditor”) to inspect, during regular business hours, the relevant records required to be maintained by the Audited Party under Section 9.11.1 or otherwise reasonably necessary to verify the accuracy of royalty reports for such Calendar Year; provided, that such audit right shall not apply to records beyond [******] from the end of the Calendar Year to which they pertain [******]. Prior to its inspection, the Auditor shall enter into a confidentiality agreement with both Parties having obligations of confidentiality and non-use no less restrictive than those set forth in Article 12 and limiting the disclosure and use of such information by such accountant to authorized representatives of the Parties and the purposes germane to Section 9.11.1. The Auditor shall report to the Auditing Party only whether the particular amounts being audited were accurate and, if not, the amount of any discrepancy, and the Auditor shall not report any other information to the Auditing Party. The Auditing Party shall treat the results of any the Auditor’s review of the Audited Party’s records as Confidential Information of the Audited Party subject to the terms of Article 12. In the event such audit leads to the discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party shall, within [******] after receipt of such report from the Auditor, pay any undisputed amount of the discrepancy. The Auditing Party shall pay the Auditor’s full cost of the audit unless the underpayment of amounts due the Auditing Party is more than [******], in which case the Audited Party shall pay the reasonable cost charged by the Auditor for such review. Any undisputed overpayments by Gilead or Agenus, as applicable, revealed by an examination shall be paid by the applicable Party within [******] of its receipt of the applicable report. [******].

. Notwithstanding anything to the contrary under this Agreement, but subject to Section 8.5 and Section 8.6, Agenus shall be solely responsible for all costs and payments of any kind (including all upfront fees, annual payments, milestone payments, and royalty payments) arising under any agreements between Agenus (or any of its Affiliates) and any Third Party, including under: (a) any Existing Upstream License Agreements and any other Upstream License Agreements, unless and until (in the case of such other Upstream License Agreements) such agreements have been accepted by Gilead pursuant to Section 8.6; and (b) any Development and Manufacturing Agreements, unless and until such agreements have been assigned to Gilead pursuant to Section 8.5, as applicable.

(a)Licensed Products. Effective as of the Option Effective Date and subject to the terms and conditions of this Agreement, Agenus hereby grants to Gilead a royalty-bearing, exclusive, transferrable (solely pursuant to Section 16.4), and sublicenseable (through multiple tiers) license, under the Agenus IP, to Develop, Manufacture, and Commercialize the Licensed Products in the Field in the Territory.

10.1.2Exclusion. For the avoidance of doubt, Agenus does not grant to Gilead pursuant to this Agreement any license under or rights to any intellectual property rights Controlled by Agenus or its Affiliates to Develop, Manufacture or Commercialize any product that [******].

10.1.3Upstream License Agreements. To the extent that the licenses granted by Agenus to Gilead under the Agenus IP pursuant to Section 10.1.1 constitute (a) the grant of a sublicense to Gilead of certain Agenus IP that is not owned by Agenus or any of its Affiliates, but that is in-licensed by Agenus or any such Affiliate from a Third Party licensor pursuant to an Upstream License Agreement or (b) the license of certain Agenus IP that is otherwise encumbered by obligations that would be binding on Gilead by their terms, then Gilead shall comply, and shall cause its Affiliates and Sublicensees to comply, with the specific obligations applicable to sublicensees under such Upstream License Agreement(s) [******].

. Gilead may subcontract to Affiliates or Third Parties the performance of tasks and obligations related to Gilead’s Development, Manufacture, and Commercialization of the Licensed Products under this Agreement as Gilead deems appropriate, which subcontract may include a sublicense of Agenus IP rights necessary for the performance of the subcontract as reasonably required.

. Gilead shall provide Agenus with [******] of each agreement with a Third Party Sublicensee (other than any agreement with a Third Party subcontractor entered into in the ordinary course of business) within [******] after the execution thereof; provided, that Gilead may [******]. Each sublicense shall require the applicable Sublicensee to comply with applicable terms and conditions of this Agreement. Gilead shall remain liable for any action or failure to act by any Sublicensee or Affiliate if such action or failure to act would have constituted a breach of this Agreement if committed by Gilead.

. Each Party retains all rights under Patents, Know-How, or other intellectual property rights Controlled by such Party which are not expressly granted to the other Party pursuant to this Agreement. Notwithstanding the foregoing, after the Option Effective Date, [******] may [******].

. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party or any of its Affiliates, as a result of this Agreement, obtain any ownership interest, license, or other right in or to any Patents, Know-How, or other intellectual property rights of the other Party, including tangible or intangible items owned, controlled, or developed by the other Party, or provided by the other Party to the receiving Party at any time, in each case, pursuant to this Agreement.

10.5.1General. Subject to Section 10.5.2, [******], Agenus shall not, and shall cause its Affiliates not to, [******].

. The determination of inventorship under this Agreement shall be made in accordance with U.S. patent laws. As between the Parties, all Inventions made or created solely by a Party’s or any of its Affiliates’ employees, independent contractors, or consultants, in the course of conducting activities under this Agreement, together with all intellectual property rights therein, shall be owned by such Party. All Inventions made or created jointly by each Party’s (or any of its Affiliates’) employees, independent contractors, or consultants, in the course of conducting activities under this Agreement, together with all Patents therein (“Joint Patents”), shall be jointly owned by the Parties (“Joint IP”). Joint IP shall be owned jointly by Gilead and Agenus on the basis of an equal, undivided interest [******] and shall be deemed to be Controlled by each Party, subject to the licenses granted under this Agreement. Notwithstanding anything to the contrary herein, each Party shall have the right to use such Joint IP, or license such Joint IP to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint IP to its Affiliates or a Third Party, in each case, without the consent of the other Party, so long as such use, sale, license, or transfer is subject to the licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement.

11.2.1Pre-Option Effective Date. Prior to the Option Effective Date, subject to Section 2.2.2, [******] shall [******] at its [******]. [******] shall [******]. [******] shall [******] with a [******], and shall [******] consistent with this Agreement [******].

11.2.3Cooperation. Each Party hereby agrees to reasonably cooperate with one another with respect to the Prosecution and Maintenance of the Agenus Patents for which such Party is responsible pursuant to this Agreement, including by: (a) making its employees, and using reasonable efforts to make its licensees, sublicensees, independent contractors, agents and consultants, reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake Prosecution and Maintenance of Patents as contemplated by this Agreement; and (b) endeavoring in good faith to coordinate its efforts with the other Party [******].

11.2.4[******]. Agenus shall, to the extent [******], use reasonable efforts, by means of [******], as reasonably determined based on [******].

11.3.1Notice. Each Party shall promptly notify the other Party of any infringement by a Third Party of any Agenus Patent in the Territory of which it becomes aware, including any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability, or non-infringement with respect to such Agenus Patent (“Infringement”). Without limiting the foregoing, Gilead shall deliver to Agenus any certification that Gilead receives pursuant to 42 U.S.C. § 262(l) or such similar laws as may exist in jurisdictions other than the United States (a “Biosimilar Notice”) with respect to a Licensed Product within [******] after receipt thereof.

11.3.2Pre-Option Effective Date. Prior to the Option Effective Date, [******] shall have [******], but not [******], to [******] in connection with [******]. [******]shall have the right to [******].

11.4.1Notice. Each Party shall promptly notify the other Party of any claim alleging that the Development, Manufacture, or Commercialization of the Licensed Products in the Territory infringes, misappropriates, or otherwise violates any Patents, Know-How, or other intellectual property rights of any Third Party (“Third Party Infringement Claim”). In any such instance, the Parties shall as soon as practicable thereafter discuss in good faith the best response to such notice of such Third Party Infringement Claim.

11.4.2Pre-Option Effective Date. Prior to the Option Effective Date, [******] shall have the [******]; provided, that, [******]. [******] shall have the right to [******].

11.4.3Post-Option Effective Date. On and after the Option Effective Date, [******] shall have the [******]; provided, that, [******].

11.5.1Any recovery received as a result of any action under Section 11.3.3(a) or Section 11.4.3, as applicable, shall be allocated in the following order: [******].

11.5.2Any recovery received as a result of any action under Section 11.3.2, Section 11.3.3(b), or Section 11.4.2, as applicable, shall be allocated in the following order: [******].

. [******] shall have the right, but not the obligation, to brand the Licensed Products using trademarks and trade names [******] for the Licensed Products, which may vary within the Territory (the “Licensed Product Marks”). [******] and shall [******].

. [******] shall: (a) with respect to requests [******]; and (b) with respect to all other requests, [******], in each case, patent term restoration (including under the Drug Price Competition and Patent Term Restoration Act), supplemental protection certificates or their equivalents, and patent term extensions consistent with this Agreement (collectively, “Patent Extensions”) with respect to the Agenus Patents, where applicable, [******]. If requested by [******] or in the event that [******], [******] shall [******] to [******] for such Patent Extensions [******], and [******] shall [******].

. Each Party agrees that a Party (the “Receiving Party”) which receives the Confidential Information of the other Party (the “Disclosing Party”) pursuant to this Agreement shall: (a) maintain in confidence such Confidential Information using not less than the efforts that such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of efforts; (b) not disclose such Confidential Information to any Third Party without first obtaining the prior written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to this Article 12; and (c) not use such Confidential Information for any purpose except those permitted under this Agreement, including, in the case of Gilead, the exercise of the rights and licenses granted to Gilead hereunder. The obligations of confidentiality, non-disclosure, and non-use under this Section 12.1 shall be in full force and effect from the Execution Date until [******] following the expiration of the Term. The Receiving Party shall return all copies of or destroy the Confidential Information of the Disclosing Party disclosed or transferred to it by the Disclosing Party pursuant to this Agreement, within [******] after the expiration or termination of this Agreement; provided, however, that a Party may retain: (i) Confidential Information of the Disclosing Party to exercise rights and licenses which expressly survive such termination or expiration pursuant to this Agreement; and (ii) one (1) copy of all other Confidential Information in archives solely for the purpose of establishing the contents thereof. In addition, [******] shall keep confidential, and shall cause its Affiliates and its and their employees, consultants, licensees, sublicensees, professional advisors, and Affiliates to keep confidential, [******] to the extent [******] on confidentiality terms at least as protective as the confidentiality provisions of this Agreement [******].

12.2.1General. Section 12.1 shall not apply with respect to any portion of the Confidential Information of the Disclosing Party to the extent that such Confidential Information:

(a)was known to the Receiving Party or any of its Affiliates, as evidenced by written records, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party;

(b)is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use;

(c)is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party, without any breach by the Receiving Party of its obligations hereunder; or

(d)is independently developed by or for the Receiving Party or any of its Affiliates, as evidenced by written records, without reference to or reliance upon the Disclosing Party’s Confidential Information.

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.

12.3.1Disclosure. Notwithstanding Section 12.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party in the following instances:

(a)subject to Section 12.5, to comply with Applicable Law (including the rules and regulations of the U.S. Securities and Exchange Commission or any national securities exchange in any jurisdiction in the Territory) (collectively, the “Securities Regulators”) or with judicial process (including prosecution or defense of litigation) if, in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance or for such judicial process (including prosecution or defense of litigation);

(b)disclosure to governmental or other regulatory agencies in order to obtain Patents, to obtain or maintain approval to conduct Clinical Trials, or to market the Licensed Products under this Agreement, in each case, in accordance with this Agreement; provided, that reasonable steps are taken to ensure confidential treatment of such Confidential Information to the extent available;

(c)disclosure to any of its officers, employees, consultants, agents, or Affiliates, and: (i) in the case of [******], any [******], (ii) in the case of [******], [******], any [******], and (iii) in the case of either Party, to such Party’s actual or potential acquirers, investors, or lenders as part of their due diligence investigations; provided, that, prior to any such disclosure, each such disclosee is bound by written obligations of confidentiality, non-disclosure, and non-use no less restrictive than the obligations set forth in this Article 12 to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement; provided, however, that, in each of the above situations in this Section 12.3.1(c), the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section 12.3.1(c) to treat such Confidential Information as required under this Article 12; and

(d)disclosure to its advisors (including attorneys and accountants) in connection with activities under this Agreement; provided, that, prior to any such disclosure, each such disclosee is bound by written obligations of confidentiality, non-disclosure, and non-use no less restrictive than the obligations set forth in this Article 12 (provided, however, that in the case of legal advisors, no written agreement shall be required), to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement; provided, however, that, in each of the above situations in this

Section 12.3.1(d), the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section 12.3.1(d) to treat such Confidential Information as required under this Article 12.

12.3.2Terms of Disclosure. If and whenever any Confidential Information is disclosed in accordance with this Section 12.3, such disclosure shall not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information other than by breach of this Agreement.

. The Parties agree that this Agreement and the terms hereof shall be deemed to be Confidential Information of both Agenus and Gilead, and each Party agrees not to disclose this Agreement or any terms hereof without obtaining the prior written consent of the other Party; provided, that each Party may disclose this Agreement or any terms hereof in accordance with the provisions of Section 12.3 or Section 12.5, as applicable.

. Each Party acknowledges and agrees that the other Party may submit this Agreement to, or file this Agreement with, the Securities Regulators or to other Persons as may be required by Applicable Law, and if a Party submits this Agreement to, or files this Agreement with, any Securities Regulator or other Person as may be required by Applicable Law, such Party agrees to consult with the other Party with respect to the preparation and submission of a confidential treatment request for this Agreement. Notwithstanding the foregoing, if a Party is required by any Securities Regulator or other Person as may be required by Applicable Law to make a disclosure of the terms of this Agreement in a filing or other submission as required by such Securities Regulator or such other Person, and such Party has: (a) provided copies of the disclosure to the other Party reasonably in advance under the circumstances of such filing or other disclosure; (b) promptly notified the other Party in writing of such requirement and any respective timing constraints; and (c) given the other Party reasonable time under the circumstances from the date of provision of copies of such disclosure to comment upon and request confidential treatment for such disclosure, then such Party shall have the right to make such disclosure at the time and in the manner reasonably determined by its counsel to be required by the Securities Regulator or the other Person. Notwithstanding the foregoing, if a Party seeks to make a disclosure as required by a Securities Regulator or other Person as may be required by Applicable Law as set forth in this Section 12.5 and the other Party provides comments in accordance with this Section 12.5, the Party seeking to make such disclosure or its counsel, as the case may be, shall use good-faith efforts to incorporate such comments.

12.6.1Subject to Section 12.3, Section 12.5, and this Section 12.6.1, [******]; provided, that [******]. The contents of any press release, publication, or other public statement that has been reviewed and approved by [******] may be re-released by [******] without first obtaining [******] prior written consent in accordance with this Section 12.6.1.

12.6.2[******]; provided, that, subject to Sections 12.3 and 12.5, any such [******]. [******] shall use [******]. If [******] shall first [******], subject to and in accordance with Section 12.3 and Section 12.5, as applicable.

12.6.3Notwithstanding the foregoing Sections 12.6.1 and 12.6.2, the Parties shall mutually agree to a press release or public announcement regarding this Agreement and the terms hereof, such press release or public announcement to be issued promptly (but in no event later than [******]) after the Execution Date, or as otherwise agreed by the Parties. Either Party shall be authorized to use the information disclosed in any mutually approved press release or public announcement without the need to seek further consent or approval thereof from the other Party.

. Except as otherwise expressly set forth herein, neither Party (or any of its respective Affiliates) shall use the name, trademark, trade name, or logo of the other Party or any of its Affiliates, or its or their respective employees, in any publicity, promotion, news release, or other public disclosure relating to this Agreement or its subject matter, without first obtaining the prior written consent of the other Party; provided, that such consent shall not be required to the extent use thereof may be required by Applicable Law, including the rules of any securities exchange or market on which a Party’s or its Affiliate’s securities are listed or traded. Each Party shall be authorized to use the name, trademark, trade name, or logo of the other Party in the manner that such other Party has previously approved, without the need to seek further consent or approval thereof from the other Party.

. For clarity, Gilead, its Affiliates, and its designees shall [******]. The Parties shall [******].

. Each Party hereby represents and warrants to the other Party, as of the Execution Date, the Option Exercise Date, and the Option Effective Date, that:

13.1.1such Party is duly organized, validly existing, and in good standing under the Applicable Law of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;

13.1.2such Party has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;

13.1.3this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to: (i) bankruptcy, insolvency, reorganization, moratorium, and other similar laws of general application affecting the rights and remedies of creditors; or (ii) laws governing specific performance, injunctive relief, and other equitable remedies;

13.1.4the execution, delivery, and performance of this Agreement by such Party does not breach or conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which such Party (or any of its Affiliates) is a party or by which such Party (or any of its Affiliates) is bound, nor violate any Applicable Law of any Governmental Authority having jurisdiction over such Party (or any of its Affiliates);

13.1.5no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency, or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or shall be necessary for, or in connection with, the transactions contemplated by this Agreement, or for the performance by it of its obligations under this Agreement, except: (i) as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials; or (ii) as set forth in Section 2.6.2(a); and

13.1.6it has obtained all necessary authorizations, consents, and approvals of any Third Party that is required to be obtained by it for, or in connection with, the transactions contemplated by this Agreement, or for the performance by it of its obligations under this Agreement, except: (i) as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials; or (ii) as set forth in Section 2.6.2(a).

. Except as set forth on Schedule 13.2, Agenus hereby represents and warrants to Gilead, as of the Execution Date, the Option Exercise Date, and the Option Effective Date, that:

13.2.1(i) Schedule 1.14 sets forth a complete and accurate list of all Agenus Patents; and (ii) [******];

13.2.7all of Agenus’s and its Affiliates’ officers, employees, and consultants: (i) have executed agreements or have existing obligations under Applicable Law requiring assignment to Agenus or its Affiliates of all inventions made during the course of and as the result of their association with Agenus or its Affiliates, as applicable, and obligating the individual to assign to Agenus or its Affiliate, as applicable, all Inventions made during the course of performance under this Agreement; [******]; and [******] have executed agreements or have existing obligations under Applicable Law obligating the individual to maintain as confidential Agenus’s Confidential Information as well as confidential information of other parties (including of Gilead and its Affiliates) that such individual may receive in its performance under this Agreement, to the extent required to support Agenus’s obligations under this Agreement;

13.2.11there are no [******] proceedings [******], or governmental investigations pending or, to the Knowledge of Agenus, threatened against Agenus or its Affiliates which could reasonably be expected to adversely affect or restrict the ability of Agenus to consummate or perform the transactions contemplated under this Agreement, [******];

13.2.14neither Agenus nor its Affiliates have entered into any agreement under which Agenus or its Affiliates: (i) has obtained a license or sublicense of rights from a Third Party to any Agenus IP; or (ii) has granted a license, sublicense, option, or right to a Third Party that remains in effect to Develop, Manufacture, or Commercialize any Licensed Product, in each case (i) and (ii), with the exception of the Existing Upstream License Agreements, the Existing Development and Manufacturing Agreements, and Ordinary Course Agreements;

13.2.15Schedule 13.2.15 sets forth a complete and accurate list of the Existing Upstream License Agreements, other than Ordinary Course Agreements, in effect as of the Execution Date. Agenus has provided Gilead or its counsel true, correct, and complete copies of each such Existing Upstream License Agreement, subject to redaction of certain terms not necessary to determining Gilead’s rights or obligations as a sublicensee of Agenus. Each such Existing Upstream License Agreement is in full force and effect, and there has been no Default of or under any such Existing Upstream License Agreement as a result of any action or omission of Agenus or its Affiliates or, to the Knowledge of Agenus, the actions or omissions of any Third Party. Agenus has not waived any of its rights under any such Existing Upstream License Agreement to which it is party. The entry into this Agreement and the contemplated activities of the Parties hereunder will not adversely affect Agenus’s rights under any Existing Upstream License Agreement;

13.2.16other than the Existing Upstream License Agreements and the Existing Development and Manufacturing Agreements, Agenus (or its Affiliates, as applicable) has not entered into any material agreement relating to (i) the Development, Manufacture, or Commercialization of any Licensed Product [******];

13.2.17Agenus has disclosed to Gilead all material information and data, and all material correspondences sent to or received from any Regulatory Authority in the possession or control of Agenus or its Affiliates, in each case, related to any Licensed Product to the extent permitted under the Prior CDA;

13.2.18except [******] or otherwise in performance of the Agenus Development Plan, Agenus has not obtained, or filed, any INDs, MAAs, or Regulatory Approvals or any other form of regulatory application for the conduct of Clinical Trials, marketing, or other purpose, for any Licensed Product, and no other Person has obtained, or filed for, any such INDs, MAAs, or Regulatory Approvals for such Licensed Products; and

. Gilead hereby represents and warrants to Agenus, as of the Execution Date, the Option Exercise Date, and the Option Effective Date, that there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial, or legal, administrative, or other proceedings or governmental investigations pending or, to the knowledge of Gilead, threatened against Gilead which would reasonably be expected to adversely affect or restrict the ability of Gilead to consummate or perform the transactions contemplated under this Agreement.

(a)Each Party hereby covenants to the other Party that such Party and its Affiliates shall perform its activities pursuant to this Agreement in compliance (and shall ensure compliance by any of its Sublicensees and subcontractors) with all Applicable Law, including, to the extent applicable, GCP, GLP, and GMP.

(b)Each Party shall immediately notify the other Party in writing if any debarment under Section 335a of Title 21 of United States Code comes to its attention with respect to any person employed or otherwise used in any capacity for performing any activities under this Agreement, and shall promptly remove such person or entity from performing any activities related to or in connection with the Agenus Development Plan or the Gilead Development Plan, to the extent applicable, or this Agreement.

(a)Neither Agenus nor any of its Affiliates shall grant any right or license to any Third Party relating to: (i) one (1) or more of the intellectual property rights within the Agenus IP; or (ii) any other right with respect to any Licensed Product, in either case (i) or (ii), which would conflict with, [******], any of the rights or licenses granted to Gilead hereunder;

(d)Agenus shall: (i) without limiting Agenus’s other obligations under this Agreement, maintain Control of all Agenus IP licensed or sublicensed to Gilead under each Existing Upstream License Agreement to the extent of Agenus’s Control of such Agenus IP as of the Execution Date, the Option Exercise Date, and the Option Effective Date, as applicable; and (ii) not terminate, breach, or otherwise Default under, or amend or modify any Existing Upstream License Agreement in a manner that would permit the counterparty thereto to terminate such Existing Upstream License Agreement or otherwise diminish the scope or exclusivity of the rights or licenses granted to Gilead with respect to any Agenus IP ([******]);

(g)Agenus shall use commercially reasonable efforts to fulfill its obligations [******] to the extent that failure to do so would materially adversely affect Gilead or its rights hereunder; and

(h)Agenus shall promptly furnish Gilead with copies of all communications received by Agenus [******], as well as all material reports and other communications that Agenus [******], in each case, to the extent any such communications or reports could reasonably affect the rights or obligations of Gilead under this Agreement. Agenus shall give Gilead, upon its request, a reasonable opportunity to review and comment upon such reports or communications before [******] and Agenus shall consider in good faith any reasonable comments timely provided by Gilead.

. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT), INCLUDING WITH RESPECT TO ANY PATENTS OR KNOW-HOW, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE, AND NON-INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL PROPERTY RIGHT. WITHOUT LIMITING THE FOREGOING, THE PARTIES AGREE THAT THE MILESTONE EVENTS, SALES MILESTONE EVENTS, AND NET SALES LEVELS SET FORTH IN THIS AGREEMENT OR THAT HAVE OTHERWISE BEEN DISCUSSED BY THE PARTIES ARE MERELY INTENDED TO DEFINE THE MILESTONE PAYMENTS, SALES MILESTONE PAYMENTS, AND ROYALTY OBLIGATIONS IF SUCH MILESTONE EVENTS, SALES MILESTONE EVENTS, OR NET SALES LEVELS ARE ACHIEVED. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP, MANUFACTURE, OR COMMERCIALIZE ANY LICENSED

PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT (LOSS) OF SUCH LICENSED PRODUCT WILL BE ACHIEVED.

. Gilead shall indemnify, defend, and hold harmless Agenus, its Affiliates, and its and their respective directors, officers, employees, agents, successors, and assigns (collectively, the “Agenus Indemnitees”) from and against any and all Damages to the extent arising out of or relating to, directly or indirectly, any Third Party Claim based upon:

provided, however, that, in each case of [******], such indemnity shall not apply to the extent Agenus has an indemnification obligation pursuant to [******] for such Damages.

. Agenus shall indemnify and hold harmless Gilead, its Affiliates, and its and their respective directors, officers, employees, agents, successors, and assigns (collectively, the “Gilead Indemnitees”), from and against any and all Damages to the extent arising out of or relating to, directly or indirectly, any Third Party Claim based upon:

provided, however, that, in each case of [******] such indemnity shall not apply to the extent Gilead has an indemnification obligation pursuant to [******] for such Damages.

. Notwithstanding the foregoing Section 14.1 and Section 14.2, any Damages in connection with any Third Party Claim incurred by or rendered against either Party or its Affiliates or other of such Party’s indemnitee’s (Agenus Indemnitees or Gilead Indemnitees, as applicable) to the extent arising from or occurring as a result of Development, Manufacture, or Commercialization activities with respect to any Profit-Share Product in the United States shall constitute [******]. If either Party learns of any Third Party Claim with respect to Damages covered by this Section 14.3, such Party shall provide the other Party with prompt written notice thereof.

14.4.1If a Party is seeking indemnification under Section 14.1 or Section 14.2, as applicable (the “Indemnitee”), it shall inform the other Party (the “Indemnitor”) of the claim giving rise

to the obligation to indemnify pursuant to Section 14.1 or Section 14.2, as applicable, as soon as reasonably practicable after receiving notice of the claim (an “Indemnification Claim Notice”); provided, that any delay or failure to provide such notice shall not constitute a waiver or release of, or otherwise limit, the Indemnitee’s rights to indemnification under Section 14.1 or Section 14.2, as applicable, except to the extent that such delay or failure materially prejudices the Indemnitor’s ability to defend against the relevant claims.

14.4.2The Indemnitor shall have the right, upon written notice given to the Indemnitee within [******] after receipt of the Indemnification Claim Notice (and, where the Indemnitor is Agenus, subject to receipt of Gilead’s prior written consent), to assume the defense of any such claim for which the Indemnitee is seeking indemnification pursuant to Section 14.1 or Section 14.2, as applicable. The Indemnitee shall cooperate with the Indemnitor and the Indemnitor’s insurer as the Indemnitor may reasonably request, and at the Indemnitor’s cost and expense. The Indemnitee shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnitor.

14.4.3The Indemnitor shall not settle any claim without first obtaining the prior written consent of the Indemnitee, not to be unreasonably withheld, conditioned, or delayed; provided, however, that the Indemnitor shall not be required to obtain such consent if the settlement: (a) involves only the payment of money and shall not result in the Indemnitee (or other Agenus Indemnitees or Gilead Indemnitees, as applicable) becoming subject to injunctive or other similar type of relief; (b) does not require an admission by the Indemnitee (or other Agenus Indemnitees or Gilead Indemnitees, as applicable); and (c) does not adversely affect the intellectual property Controlled by, or the rights or licenses granted to the Indemnitee (or its Affiliate) under this Agreement. The Indemnitee shall not settle or compromise any such claim without first obtaining the prior written consent of the Indemnitor.

14.4.4If the Parties cannot agree as to the application of Section 14.1 or Section 14.2, as applicable, to any claim, pending the resolution of the dispute pursuant to Section 16.6, the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 14.1 or Section 14.2, as applicable, upon resolution of the underlying claim. In each case, the Indemnitee shall reasonably cooperate with the Indemnitor and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information shall be subject to Article 12.

14.5.1Insurance Maintained by each Party. During the Term, each Party shall have and maintain in full force and effect, at its own expense, insurance coverage to include:

(a)Commercial general liability insurance, including personal and advertising injury, with limits of liability not less than [******]. General liability limit requirements may be satisfied by a combination of primary and umbrella or excess liability insurance coverage; and

(b)Workers’ compensation insurance in compliance with Applicable Law (including the local law requirements of the state or jurisdiction in which the work is to be performed). Employer’s liability insurance in amounts not less than [******]. Where permitted by Applicable Law, such policies shall contain a waiver of the insurer’s subrogation rights against the non-insured Party.

(a)Additional Insured. Each Party shall name the other Party as an additional insured on the insurance policies maintained pursuant to Section 14.5.1(a), either by endorsement or blanket additional insured endorsement.

(b)Evidence of Insurance. Each Party will provide evidence of insurance maintained pursuant to this Section 14.5 on request of the other Party.

(c)Notice of Cancellation. Each Party will provide the other Party a notice of insurance policy cancellation in accordance with the provisions of the applicable insurance policy maintained pursuant to this Section 14.5.

(d)Policy Type. Insurance policies maintained pursuant to this Section 14.5 should be occurrence type. If policies maintained pursuant to this Section 14.5 are claims made, then insurance shall be maintained for at least [******] following expiration or termination of this Agreement.

(e)Insurance Carrier Rating. All insurance maintained pursuant to this Section 14.5 will be underwritten by companies with an AM best rating of at least [******].

15.1.1Term. Except for the terms and conditions of Article 1 (to the extent the definitions are used in the following provisions), Article 12, Article 13, Article 16, this Section 15.1.1, and Section 15.7.1 (all of which shall become effective on the Execution Date), this Agreement shall become effective on the License Agreement Effective Date (the “Effective Date”); provided, that, unless earlier terminated in accordance with this Article 15, this Agreement shall remain in effect and expire upon the earliest of: (a) the expiration of the Option Period, if Gilead does not exercise the Option in accordance with Section 2.4; (b) the delivery of written notice of termination by a Party to the other Party, where the Option Effective Date has not occurred on or prior to [******] after the Option Exercise Date; and (c) on or after the Option Effective Date: (i) for Royalty-Bearing Products, on a Royalty-Bearing Product-by-Royalty-Bearing Product and country-by-country basis, upon the expiration of the Royalty Term with respect to such Royalty-Bearing Product in such country; and (ii) for Profit-Share Products, on a Profit-Share Product-by-Profit-Share Product basis, upon the expiration of the Profit-Share Term with respect to such Profit-Share Product (the “Term”).

(a)Upon the expiration of the Term pursuant to Section 15.1.1(a) or Section 15.1.1(b):

(1)subject to Section 15.1.2(a)(2) and Section 15.7, all rights and obligations of the Parties under this Agreement shall terminate, except as set forth in this Article 15; and

(b)Upon the expiration of the Term pursuant to Section 15.1.1(c), the following terms shall apply:

(1)Licenses after Licensed Product Expiration. Upon the expiration of the Term pursuant to Section 15.1.1(c) with respect to (i) a given Royalty-Bearing Product in a given country or (ii) a given Profit-Share Product, the license set forth in Section 10.1.1(a) with respect to such Royalty-Bearing Product in such country or such Profit-Share Product in the U.S., as applicable, shall become fully paid-up, perpetual, irrevocable, and royalty-free.

(2)Licenses after Expiration of Agreement. Upon the expiration of the Term with respect to this Agreement in its entirety pursuant to Section 15.1.1(c), the license set forth in Section 10.1.1(a) with respect to all Licensed Products in all countries in the Territory shall become fully paid-up, perpetual, irrevocable, and royalty-free.

15.2.1Material Breach. This Agreement may be terminated in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis by a Party for a Material Breach by the other Party; provided, that the breaching Party has not cured such breach within [******] after the date of written notice to the breaching Party of such breach (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement (in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis). Notwithstanding the foregoing, for any breach of this Agreement with respect to any undisputed payment obligation, the Cure Period shall be [******]. Any termination of this Agreement (in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis) under this Section 15.2.1 shall become effective [******], unless the breaching Party has cured such breach prior to the expiration of such Cure Period, or, if such breach is not susceptible to cure within the Cure Period, then, except with respect to any breach of any undisputed payment obligation, such Cure Period shall be extended for [******].

15.2.2Disagreement as to Material Breach. Notwithstanding Section 15.2.1, if the Parties in good faith disagree as to whether there has been a Material Breach of this Agreement, then: (a) the Party that disputes whether there has been a Material Breach may contest the allegation by referring such matter, within [******] following its receipt of notice of alleged Material Breach, for resolution in accordance with Section 16.7.1(a); (b) the relevant Cure Period with respect to such alleged Material Breach shall be [******].

. Gilead may terminate this Agreement at will, in its sole discretion, in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis at any time upon [******] prior written notice to Agenus.

15.4.1If either Party makes a general assignment for the benefit of, or an arrangement or composition generally with, its creditors, appoints or suffers appointment of an examiner or of a receiver or trustee over all or substantially all of its property, passes a resolution for its winding up, or files a petition under any bankruptcy or insolvency act or law or has any such petition filed against it which is not dismissed, discharged, bonded, or stayed within [******] after the filing thereof and seeks to reject this Agreement, (a “Rejection Event”), the other Party may treat this Agreement as terminated by such rejection, effective immediately upon written notice to such Party.

15.4.2For purposes of Section 365(n) of the U.S. Bankruptcy Code (the “Code”) and any similar laws in any other country, all rights and licenses granted under or pursuant to any Section of this Agreement are rights to “intellectual property” (as defined in Section 101(35A) of the Code). The Parties agree that the licensee of such rights under this Agreement will retain and may fully exercise all of its protections, rights and elections under the Code and any similar laws in any other country. Each Party hereby acknowledges that (a) copies of research data, (b) laboratory samples, (c) product samples, (d) formulas, (e) laboratory notes and notebooks, (f) data and results related to clinical trials, (g) regulatory filings and approvals, (h) rights of reference in respect of regulatory filings and approvals, (i) pre-clinical research data and results, and (j) marketing, advertising and promotional materials, in each case, that relate to such intellectual property, constitute “embodiments” of such intellectual property pursuant to Section 365(n) of the Code, and that the licensee will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it upon its written request therefor and election under Bankruptcy Code Section 365(n)(1)(B) to retain the licenses granted by Agenus to Gilead hereunder in the event of Agenus’s rejection of this Agreement, unless the licensor elects to continue to perform all of its obligations under this Agreement. The provisions of this Section 15.4.2 are without prejudice to any rights the non-subject Party may have arising under the Code, laws of other jurisdictions governing insolvency and bankruptcy, or other Applicable Law. The Parties agree that they intend the following rights to extend to the maximum extent permitted by law, including for purposes of the Code and any similar laws in any other country: (x) the right of access to any intellectual property (including all embodiments thereof) of the licensor, or any Third Party with whom the licensor contracts to perform an obligation of such licensor under this Agreement which is necessary for the Development or Commercialization of a Licensed Product; (y) the right to contract directly with any Third Party described in (x) to complete the contracted work, and (z) the right to cure any breach of or default under any such agreement with a Third Party and set off the costs thereof against amounts payable to such licensor under this Agreement.

15.5.1Termination by Gilead at Will or by Agenus for Material Breach or Bankruptcy. Upon termination of this Agreement with respect to a Terminated Licensed Product: (a) by Gilead, in accordance with Section 15.3; or (b) by Agenus, in accordance with Section 15.2 or Section 15.4.

(a)the license granted by Agenus to Gilead pursuant to Section 10.1.1(a) with respect to the Terminated Licensed Product shall terminate and Gilead shall not have any rights to use or exercise any rights under the Agenus IP with respect to such Terminated Licensed Product;

(b)Gilead shall be released from its Development, Manufacturing, and Commercialization obligations under this Agreement with respect to the Terminated Licensed Product, including with respect to Section 4.3 and Section 4.4;

(c)Gilead shall as soon as reasonably practicable transfer and assign (to the extent permitted) to Agenus all Regulatory Materials owned and controlled by Gilead or its Affiliates, in each case, at Agenus’s cost, to the extent solely related to the Terminated Licensed Product and necessary for Developing, Manufacturing, or Commercializing such Terminated Licensed Product in the Field in the Territory; provided, that Gilead may retain a copy of such items for its records;

(e)upon receipt by Gilead from Agenus of written notice no later than the [******], the Parties shall [******];

(f)in the event that Gilead does not receive written notice from Agenus within [******] pursuant to Section 15.5.1(e), then [******];

(g)in the case of termination of this Agreement in its entirety, any and all sublicense agreements entered into by Gilead or any of its Affiliates with a Sublicensee pursuant to this Agreement shall survive such termination of this Agreement, except to the extent that: (i) any such Sublicensee is in material breach of this Agreement or such sublicense; or (ii) Agenus elects to grant such Sublicensee a direct license of the sublicensed rights on the same terms applicable to Gilead under this Agreement. Gilead shall, upon the written request of Agenus, assign any such sublicense (to the extent not terminated pursuant to the preceding sentence) to Agenus or its Affiliates and, upon such assignment, Agenus or its Affiliates, as applicable, shall assume such sublicense;

(h)each Party shall comply with the return and destruction obligations with respect to Confidential Information and any Know-How of the other Party that are in its or its Affiliates’, sublicensees’ or Third Party contractors’ possession or control in accordance with Article 12;

(i)to the extent that Gilead is manufacturing the Terminated Licensed Product as of the effective date of termination, then, upon the election of Agenus, exercised by written notice to Gilead no later than [******] following the effective date of termination, the Parties shall negotiate and use good-faith efforts to enter into:

(1)a supply agreement (and a corresponding quality agreement with customary terms and conditions) pursuant to which Gilead would supply Agenus’s requirements of the Terminated Licensed Product [******] and which would include such other mutually agreed terms as are customary for agreements of such type; or

(2)an agreement under which Gilead would provide, and cause its Affiliates to provide, [******];

(j)to the extent that a Third Party manufacturer is manufacturing the Terminated Licensed Product as of the effective date of termination, then, to the extent Gilead has the right to do so under its agreements with its Third Party manufacturers, upon the election of Agenus, exercised by written notice to Gilead no later than [******] following the effective date of termination, and at Agenus’s expense, Gilead shall [******];

(k)upon the election of Agenus, exercised by written notice to Gilead no later than [******] following the effective date of termination, at Agenus’s expense, Gilead shall assign, and shall cause its Affiliates and Sublicensees to assign, to Agenus or its designee, all of Gilead’s rights under Third Party contracts relating to the Development, Manufacture, or Commercialization of the Terminated Licensed Product, to the extent that such contracts can be assigned without the counterparty’s consent and to the extent such contracts relate solely to the Terminated Licensed Product. To the extent that such consent is required, [******]; and Agenus shall assume Gilead’s obligations under such assigned contracts, except to the extent such obligations relate to the period of performance prior to assignment or to any breach of such agreements by Gilead, its Affiliates, or its Sublicensees; and

(l)if, as of the effective date of termination, Gilead or its Affiliates are conducting any Clinical Trials for the Terminated Licensed Product, then the Parties shall in good faith discuss and agree upon the appropriate completion or transition of such Clinical Trials to Agenus, subject to Applicable Law.

15.5.2Termination by Gilead for Material Breach or Bankruptcy. Upon termination of this Agreement with respect to a Terminated Licensed Product by Gilead in accordance with Section 15.2 or Section 15.4:

(a)the licenses granted by Agenus to Gilead pursuant to Section 10.1.1(a) with respect to the Terminated Licensed Product shall terminate and Gilead shall not have any rights under the Agenus IP with respect to such Terminated Licensed Product;

(c)Each Party shall comply with the return and destruction obligations with respect to Confidential Information and any Know-How of the other Party that are in its or its Affiliates’, sublicensees’ or Third Party contractors’ possession or control in accordance with Article 12.

15.7.1Accrued Rights; Remedies. The expiration or termination of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such expiration or termination, and any and all damages or remedies (whether at law or in equity) arising from any breach hereunder, each of which shall survive expiration or termination of this Agreement. Such expiration or termination shall not relieve any Party from obligations which are expressly indicated to survive expiration or termination of this Agreement. Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article are in addition to any other relief and remedies available to either Party under this Agreement, at law, or in equity.

15.7.2Survival. Without limiting the provisions of Section 15.7.1, the rights and obligations of the Parties set forth in the following Sections and Articles of this Agreement shall survive the expiration or termination of this Agreement (to the extent in effect as of the Effective Date), in addition to those other terms and conditions that are expressly stated to survive termination or expiration of this Agreement: [******].

. If one (1) or more of the terms or provisions of this Agreement is held by a court of competent jurisdiction to be void, invalid, or unenforceable in any situation in any jurisdiction, such holding shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the void, invalid, or unenforceable term or provision in any other situation or in any other jurisdiction, and the term or provision shall be considered severed from this Agreement solely for such situation and solely in such jurisdiction, unless the void, invalid, or unenforceable term or provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the void, invalid, or unenforceable term or provision. If the final judgment of such court declares that any term or provision hereof is void, invalid, or unenforceable, the Parties agree to: (a) reduce the scope, duration, area, or applicability of the term or provision or to delete specific words or phrases to the minimum extent necessary to cause such term or provision as so reduced or amended to be enforceable; and (b) make a good-faith effort to replace any void,

invalid, or unenforceable term or provision with a valid and enforceable term or provision such that the objectives contemplated by the Parties when entering this Agreement may be realized.

. Any notice required or permitted to be given by this Agreement shall be in writing and in English and shall be: (a) delivered by hand or by overnight courier with tracking capabilities; or (b) mailed postage prepaid by first class, registered, or certified mail, in each case, addressed as set forth below unless changed by notice so given:

Any such notice shall be deemed given on the date received, except any notice received after 5:30 p.m. (in the time zone of the receiving Party) on a Business Day or received on a non-Business Day shall be deemed to have been received on the next Business Day. A Party may add, delete, or change the person or address to which notices should be sent at any time upon written notice delivered to the other Parties in accordance with this Section 16.2.

. A Party shall not be liable for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to a cause beyond the reasonable control of such Party, including acts of God, fires, earthquakes, acts of war, terrorism, or civil unrest, or hurricane or other inclement weather; provided, that the affected Party: (a) promptly notifies the other Party; and (b) shall use its commercially reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance in accordance with the terms of this Agreement whenever such causes are removed. When such circumstances arise, the Parties shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.

. Except as provided in this Section 16.4, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party; provided, however, that (and notwithstanding anything elsewhere in this Agreement to the contrary but without prejudice to Section 9.10.2(b)) either Party may, without such consent, assign this Agreement and its rights and obligations hereunder in whole or in part: (a) to an Affiliate of such Party; (b) in connection with the transfer or sale of all or substantially all of its assets or business related to the subject matter of this Agreement; or (c) pursuant to a merger or consolidation (or similar transaction) of the assigning Party. In addition, Gilead may, without the consent of Agenus, assign its rights and obligations under this Agreement to a Third Party, where Gilead or its Affiliate divest rights to a Licensed Product or Licensed Antibody. Any attempted assignment not in accordance with this Section 16.4 shall be void. In the event that a permitted assignment of this Agreement by a Party increases the tax liability of the other Party or any of its Affiliates over the amount of any Taxes that otherwise would have been payable in the absence of such assignment, the assigning Party shall reimburse the other Party for the amount of such increased Tax liability.

. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion. No waiver, modification, release, or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by the Parties.

16.6.1Choice of Law. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and interpreted in accordance with the laws of the State of New York, without giving effect to any choice of law rules. The provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement or any subject matter hereof.

. THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY SHALL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT, OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY, AND BARGAINED-FOR AGREEMENT BETWEEN THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT, AND SUCH PROCEEDING SHALL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.

(a)Except as otherwise set forth in this Agreement, in the event of an unresolved matter, dispute, or issue relating to the breach or alleged breach or interpretation of this Agreement (“Dispute”), the Parties shall refer the Dispute to the Executive Officers for discussion and resolution. If the Executive Officers are unable to resolve such Dispute within [******] of the Dispute being referred to them by either Party in writing, then the Dispute shall be resolved as provided in Section 16.7.1(b) or Section 16.7.1(c), as applicable.

(b)Any unresolved Disputes between the Parties arising out of or in connection with this Agreement shall be resolved by final and binding arbitration. Whenever a Party decides to institute arbitration proceedings, it shall give written notice to that effect to the other Party. Arbitration shall be held in New York, New York, according to the Rules of Arbitration of the International Chamber of Commerce (“ICC Rules”) in effect at the Effective Date, except as they may be modified herein or by mutual agreement of the Parties. All arbitration proceedings shall be conducted by three (3) arbitrators unless otherwise mutually agreed by the Parties. The claimant and the respondent shall each nominate an arbitrator in accordance with the ICC Rules, and the third arbitrator, who shall be the president of the arbitral tribunal, shall be appointed by the two (2) Party-appointed arbitrators in consultation with the Parties. The Parties undertake to maintain confidentiality as to the existence of the arbitration proceedings and as to all submissions, correspondence, and evidence relating to the arbitration proceedings. This Section 16.7.1(b) shall survive the termination of the arbitral proceedings. No arbitrator (nor any arbitral tribunal) shall [******]. Decisions of the arbitrator(s) shall be final and binding on the Parties. Judgment on the award so rendered may be entered in any court of competent jurisdiction. The costs of the arbitration shall be shared by the Parties during the course of such arbitration, as assessed by the International Chamber of Commerce, and shall be borne as determined by the arbitrator(s). With respect to any dispute over the [******], within [******] after the arbitrators are selected pursuant this Section 16.7.1(b), each Party shall provide the arbitrators and the other Party a proposal (including a written memorandum in support of its position) for the [******]. In rendering a decision regarding the [******], the arbitrators shall select the proposal which is more commercially reasonable under the circumstances (or, if a Party fails to submit a proposal within such [******] period, the other Party’s proposal).

(c)Notwithstanding anything to the contrary, either Party may at any time seek to obtain preliminary injunctive relief or other applicable provisional relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief. A request by a Party to a court of competent jurisdiction for interim measures necessary to preserve the Party’s rights, including attachments or injunctions, shall not be deemed incompatible with, or a waiver of, the agreement to mediate or arbitrate contained in this Section 16.7.1(c), or the availability of interim measures of protection under the ICC Rules. Notwithstanding anything to the contrary in this Section 16.7.1(c), any disputes regarding the scope, validity, enforceability, or inventorship of any Patents shall be submitted for final resolution by a court of competent jurisdiction.

. Agenus and Gilead are independent contractors under this Agreement. Nothing contained herein is intended or is to be construed so as to constitute either Party as a partner, agent, or joint venturer of the other Party. Neither Agenus nor Gilead, respectively, shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of Agenus and Gilead, respectively, or to bind Agenus and Gilead, respectively, to any contract, agreement, or undertaking with any Third Party.

. Except as otherwise specified in this Agreement, each Party shall bear its own costs and expenses (including investment banking and legal fees and expenses) incurred in connection with this Agreement and the transactions contemplated hereby.

. There are no express or implied Third Party beneficiaries hereunder. The provisions of this Agreement are for the exclusive benefit of the Parties, and no other person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party, except for the indemnification rights of the Agenus Indemnitees pursuant to Section 14.1 and Section 14.4 and the Gilead Indemnitees pursuant to Section 14.2 and Section 14.4.

. This Agreement, together with the attached Exhibits and Schedules, contains the entire agreement by the Parties with respect to the subject matter hereof and supersedes any prior express or implied agreements, understandings, and representations, either oral or written, which may have related to the subject matter hereof in any way, including the Prior CDA and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date; provided, that this Agreement shall not supersede the terms and provisions of the Prior CDA applicable to any period prior to the Effective Date.

. This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together, and shall constitute one (1) and the same instrument. Any such counterpart, to the extent delivered by means of facsimile by .pdf, .tif, .gif, .jpeg, or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each Party forever waives any such defense, except to the extent that such defense relates to lack of authenticity.

. Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at law or in equity. The Parties further agree not to raise as a defense or objection to the request or granting of such relief that any breach of this Agreement is or would be compensable by an award of money damages. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Law.

16.14.1Generally. This Agreement has been diligently reviewed by and negotiated by and between the Parties, and in such negotiations each of the Parties has been represented by competent (in-house or external) counsel, and the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.

(a)The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined and, where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding meaning.

(b)Whenever the context may require, any pronoun shall include the corresponding masculine, feminine, and neuter forms.

(c)The word “will” shall be construed to have the same meaning and effect as the word “shall.”

(d)The words “including,” “includes,” “include,” “for example,” and “e.g.,” and words of similar import, shall be deemed to be followed by the words “without limitation.”

(e)The word “or” shall be interpreted to mean “and/or,” unless the context requires otherwise.

(f)The words “hereof,” “herein,” and “herewith,” and words of similar import, shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement.

(g)Unless the context requires otherwise or otherwise specifically provided: (i) all references herein to Articles, Sections, Schedules, or Exhibits shall be construed to refer to Articles, Sections, Schedules, and Exhibits of this Agreement; and (ii) reference in any Section to any subclauses are references to such subclauses of such Section.

16.14.3Subsequent Events. Unless the context requires otherwise: (a) any definition of or reference to any agreement, instrument, or other document herein shall be construed as referring to such agreement, instrument, or other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements, or modifications set forth herein); (b) any reference to any Applicable Law herein shall be construed as referring to such Applicable Law as from time to time enacted, repealed, or amended; and (c) subject to Section 16.4, any reference herein to any Person shall be construed to include the Person’s successors and assigns.

16.14.4Headings. Headings, captions, and the table of contents are for convenience only and shall not be used in the interpretation or construction of this Agreement.

16.14.5Prior Drafts. No prior draft of this Agreement shall be used in the interpretation or construction of this Agreement.

. Each Party shall execute, acknowledge, and deliver such further instruments, and do all such other ministerial, administrative, or similar acts, as may be reasonably necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement.

. Except as expressly set forth otherwise in this Agreement, each Party shall have the right to extend the rights and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement, except this right to extend, shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to the Party extending such rights and obligations. The Party extending the rights and obligations granted hereunder shall remain primarily liable for any acts or omissions of any of its Affiliates.

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this OPTION AND LICENSE AGREEMENT (AGEN1223) to be executed by their respective duly authorized officers as of the Execution Date.